{"title":"Farmaci e Cerotti Antidolorifici Topici","description":"\u003cp\u003eAntinfiammatori e antidolorifici da applicare sulla pelle invece che da ingerire: gel e schiume cutanee a base di diclofenac, ketoprofene e ibuprofene, cerotti medicati a rilascio prolungato, pomate revulsive. Agiscono sul punto dolente per contratture, strappi, distorsioni, mal di schiena e dolori articolari. Spedizione veloce in 24\/48 ore.\u003c\/p\u003e","products":[{"product_id":"dicloreum-antinfiammatorio-locale-10-cerotti-medicati-180-mg","title":"Dicloreum Local Anti-inflammatory 10 Medicated Patches 180 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA 180 mg medicated plaster contains: Active ingredient: Diclofenac hydroxyethylpyrrolidine 180 mg (equal to 140 mg of sodium Diclofenac) Excipients with known effects: 14 mg of methyl parahydroxybenzoate (E218), 7 mg of propyl parahydroxybenzoate (E216), 420 mg of propylene glycol and 2.8 mg of perfume (containing amyl cinnamale, amyl cinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate). For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGelatin, Povidone, D-Sorbitol 70% solution, Kaolin, Titanium dioxide, Propylene glycol, Methyl parahydroxybenzoate (E218), Propyl parahydroxybenzoate (E216), Disodium edetate, Tartaric acid, Dihydroxyaluminium aminoacetate, Sodium caramel, Sodium polyacrylate, 1,3-butylene glycol, Polysorbate 80, Perfume, Purified water, Synthetic felt, Plastic film.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to diclofenac, acetylsalicylic acid or other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients of the finished product, as well as to isopropanol. • Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal inflammatory drugs (NSAIDs). • Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. • Third trimester of pregnancy and breastfeeding (see section 4.6). • Patients with active peptic ulcer. \u003ci\u003eChildren and adolescents:\u003c\/i\u003e Use in children and adolescents under 16 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. \u003cu\u003eDosage\u003c\/u\u003e The product should only be applied to intact, healthy skin and should not be applied when bathing or showering. The diclofenac medicated plaster must be used for the shortest time possible in relation to the indication of use. \u003ci\u003eAdults\u003c\/i\u003e The usual dosing regimen is 1 or 2 patches (or any other frequency evaluated in clinical studies for a specific product) per day (one application every 12 or 24 hours) for a period of up to 14 days (or for any other number of days the use has been evaluated in clinical studies for a specific product). If there is no improvement following the recommended treatment period, you should consult a doctor \u003ci\u003eChildren and adolescents under 16 years of age:\u003c\/i\u003e The use of this medicated plaster is not recommended in children and adolescents under 16 years of age because insufficient data are available to evaluate the safety and effectiveness of the medicine (see section 4.3). In adolescents aged 16 years and older, if the product is needed for a treatment period of more than 7 days for pain relief or if symptoms worsen, the patient or relatives of the adolescent are advised to consult a doctor. \u003ci\u003eElderly\u003c\/i\u003e This medicine should be used with caution in elderly patients as they are more predisposed to side effects (see section 4.4). \u003ci\u003ePatients with hepatic or renal insufficiency\u003c\/i\u003e For the use of diclofenac medicated plasters in patients with hepatic or renal insufficiency, consult section 4.4. \u003cu\u003eMethod of administration\u003c\/u\u003e Cut the bag containing the medicated plaster as indicated. Remove a medicated plaster, remove the plastic film used to protect the adhesive surface and apply the plaster to the joint or painful surface. If necessary, the patch can be held in place using an elastic band. Carefully close the envelope by pressing the edge where the closing cord is located. The patch must be used whole.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at a temperature not exceeding 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf diclofenac medicated plasters are used on large skin surfaces and for a prolonged period of time, the possibility of systemic adverse events cannot be excluded (see the Summary of Product Characteristics of the systemic formulations of diclofenac). The medicated plaster must be applied only to intact and healthy skin and must not be applied to damaged skin or open wounds. The patches should not come into contact with the eyes or mucous membranes. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. - Do not use with an occlusive dressing that does not allow air to pass through. - Treatment must be stopped immediately if a skin rash develops after application of the medicated plaster. - Do not simultaneously administer topically or systemically another medicinal product based on diclofenac or other NSAIDs. - Although systemic effects should be limited, the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or bleeding diathesis. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients who are more predisposed to side effects. - Patients should be advised not to expose themselves to direct sunlight or light from sunlamps for approximately one day after removal of the medicated plaster in order to reduce the risk of photosensitivity. Local anti-inflammatory Dicloreum contains: - methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (even delayed). - 420 mg of propylene glycol per patch which may cause skin irritation. - a perfume containing allergens (amyl cinnamale, amyl cinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate) which may cause reactions allergic.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, the most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); Not known: cannot be estimated from available data.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the risk\/benefit ratio of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported with diclofenac medicated plasters. Should systemic side effects occur due to incorrect use or accidental overdose (e.g. in children) with the product, the general supportive measures to be taken in case of intoxication with non-steroidal anti-inflammatory drugs are recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e The systemic concentration of diclofenac, compared to oral formulations, is lower after topical administration. Referring to the experience of treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may have negative effects on pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of diclofenac medicated plasters, no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, diclofenac medicated plasters should not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe application of diclofenac medicated plasters does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":40207822913651,"sku":"042685014","price":23.81,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-dicloreum-antinfiammatorio-locale-10-cerotti-medicati-180-mg-farmacia-dottor-tili-1254211180.jpg?v=1786732718"},{"product_id":"voltaren-emulgel-gel-60-gr-2","title":"Voltaren Emulgel Gel 60 Gr 2%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory conditions of a rheumatic or traumatic nature affecting the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons, and ligaments (such as tendinitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of \u003ci\u003eVoltaren Emulgel\u003c\/i\u003e contain 2.32 g of diclofenac diethylammonium, equivalent to 2 g of diclofenac sodium. Excipients with known effects: propylene glycol (50 mg\/g of gel); butylated hydroxytoluene (0.2 mg\/g of gel); pungent eucalyptus fragrance. For the full list of excipients, see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eButylated hydroxytoluene\u003c\/b\u003e, carbomers, cocoyl caprylocaprate, diethylamine, isopropyl alcohol, liquid paraffin, cetostearyl ether of macrogol, oleyl alcohol, \u003cb\u003epropylene glycol\u003c\/b\u003e, \u003cb\u003epungent eucalyptus fragrance\u003c\/b\u003e, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • History of asthma, angioedema, urticaria, or acute rhinitis following the intake of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). • During the third trimester of pregnancy. • Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cp\u003eFor cutaneous use.\u003c\/p\u003e \u003cb\u003eAdults over 18 years:\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e provides pain relief for up to 12 hours: Apply \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e twice a day to the area to be treated (preferably in the morning and evening), rubbing in lightly. The amount to apply depends on the size of the affected area. For example, 2–4 g of Voltaren Emulgel 2% gel (an amount ranging in size from a cherry to a walnut) is sufficient to treat an area of 400–800 cm\u0026sup2;. After application, clean your hands with absorbent paper and then wash them, unless the hands are the site to be treated. The absorbent paper should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before taking a shower or bath. Warning: use only for short treatment periods. The duration of treatment depends on the indication for use and the clinical response. The gel should not be used for more than 14 days without a doctor's advice. Consult a doctor if symptoms persist or worsen after 7 days of treatment. \u003cb\u003eAdolescents from 14 to 18 years old:\u003c\/b\u003e Apply Voltaren Emulgel 2% gel twice a day to the area to be treated (preferably in the morning and evening), rubbing in gently. The amount to be applied depends on the size of the affected area. For example, 2-4 g of Voltaren Emulgel 2% gel (an amount ranging in size from a cherry to a walnut) is sufficient to treat an area of 400-800 cm\u0026sup2;. After application, clean hands with absorbent paper and then wash them, unless they are the site to be treated. The absorbent paper should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. If this product is needed for more than 7 days to relieve pain or if symptoms worsen, consult a doctor. \u003cb\u003eChildren under 14 years:\u003c\/b\u003e There are insufficient data on the efficacy and safety in children and adolescents under 14 years (see paragraph 4.3 Contraindications). Therefore, the use of Voltaren Emulgel 2% gel is contraindicated in children under 14 years of age. \u003cb\u003eElderly (over 65 years)\u003c\/b\u003e The usual adult dosage can be used.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSTORAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e cannot be excluded if the preparation is used on large areas of skin and for a prolonged period\u003ci\u003e.\u003c\/i\u003e \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e should be applied only on intact, healthy skin, and not on skin wounds or open lesions. It should not come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if a skin rash develops after application of the product. \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains 200 mg of propylene glycol per dose (4 g), equivalent to 50 mg\/g, which may cause skin irritation. \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains butylated hydroxytoluene which may cause localized skin reactions (e.g., contact dermatitis) or irritation of the eyes and mucous membranes. \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains pungent eucalyptus fragrance, an aroma that in turn contains benzyl alcohol, citronellol, coumarin, d-limonene, eugenol, geraniol, linalool which may cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eADVERSE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse effects include mild and transient skin reactions at the application site. In very rare cases, allergic reactions may occur. The adverse effects (Table 1) are listed below by organ, system, and MedDRA frequency. Frequencies are defined as: very common (≥ 1\/10); common (≥ 1\/100 to \u003c1\/10); uncommon (≥ 1\/1,000 to \u003c1\/100); rare (≥ 1\/10,000 to \u003c1\/1,000); very rare (\u003c 1\/10,000); unknown (frequency cannot be estimated from the available data). \u003cb\u003eTable 1\u003c\/b\u003e \u003ctable border=1 cellspacing=0 cellpadding=3\u003e \u003ctr\u003e \u003ctd colspan=2\u003e \u003cb\u003eInfections and infestations\u003c\/b\u003e \u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Very rare\u003c\/td\u003e \u003ctd\u003e Rash with pustules.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd colspan=2\u003e \u003cb\u003eImmune system disorders\u003c\/b\u003e \u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Very rare\u003c\/td\u003e \u003ctd\u003e Hypersensitivity (including urticaria), angioedema.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd colspan=2\u003e \u003cb\u003eRespiratory, thoracic, and mediastinal disorders\u003c\/b\u003e \u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Very rare\u003c\/td\u003e \u003ctd\u003e Asthma.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd colspan=2\u003e \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e \u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Common\u003c\/td\u003e \u003ctd\u003e Dermatitis (including contact dermatitis), rash, erythema, eczema, itching.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Rare\u003c\/td\u003e \u003ctd\u003e Bullous dermatitis.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Very rare\u003c\/td\u003e \u003ctd\u003e Photosensitivity reaction, allergic reactions.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Unknown\u003c\/td\u003e \u003ctd\u003e Burning sensation at the application site, dry skin.\u003c\/td\u003e \u003c\/tr\u003e \u003c\/table\u003e \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e The reporting of suspected adverse reactions that occur after the medicinal product has been authorized is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are requested to report any suspected adverse reaction via the national reporting system at the address: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of topical diclofenac makes an overdose very unlikely; however, adverse effects similar to those observed after an overdose of diclofenac tablets can be expected if Voltaren Emulgel 2% is ingested (1 tube of 60 g contains the equivalent of 1.2 g of diclofenac sodium). In case of ingestion leading to significant systemic adverse effects, general therapeutic measures normally adopted for treating poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Further treatment procedures, within a short time after ingestion, should take into account clinical indications or recommendations from the poison center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac compared with oral formulations is lower after topical administration. Referring to the experience with NSAID treatment via systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryonic\/fetal development. Results from epidemiological studies suggest an increased risk of miscarriage and of heart malformations and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of heart malformations increases from less than 1% to about 1.5%. It is believed that the risk increases with the dose and the duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and mortality. embryo-fetal; moreover, an increased incidence of various malformations, including cardiovascular ones, has been reported in animals that were administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman planning to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which may progress to renal failure with oligohydramnios; the mother and the neonate, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-platelet effect that can occur even at very low doses; - inhibition of uterine contractions resulting in delay or prolongation of labor. Diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small amounts. However, at the therapeutic doses of \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e, no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this case, \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e should not be applied to the breasts of nursing mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see paragraph 4.4 Special warnings and precautions for use).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON ABILITY TO DRIVE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e does not impair the ability to drive vehicles or use machinery.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":40207823929459,"sku":"034548065","price":13.67,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/novartis-farma-spa-voltaren-emulgel-gel-60-gr-2-farmacia-dottor-tili-1213792743.webp?v=1767125980"},{"product_id":"voltaren-emulgel-gel-2-100-gr","title":"Voltaren Emulgel Gel 2% 100 Gr","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons and ligaments (such as tendonitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of \u003ci\u003eVoltaren Emulgel\u003c\/i\u003e contain 2.32 g of diclofenac diethylammonium, equivalent to 2 g of diclofenac sodium. Excipients with known effects: propylene glycol (50 mg\/g gel); butylated hydroxytoluene (0.2 mg\/g of gel); pungent eucalyptus perfume For the complete list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eButylated hydroxytoluene\u003c\/b\u003e, carbomers, cocoyl caprylocaprate, diethylamine, isopropyl alcohol, liquid paraffin, macrogol cetostearyl ether, oleic alcohol, \u003cb\u003epropylene glycol\u003c\/b\u003e, \u003cb\u003epungent eucalyptus scent\u003c\/b\u003e, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • History of asthma, angioedema, urticaria or acute rhinitis following the intake of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). • During the third trimester of pregnancy. • Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAdults over 18 years:\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e provides pain relief for up to 12 hours: Apply \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e 2 times a day on the area to be treated (preferably in the morning and evening), rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 2-4 g of Voltaren Emulgel 2% gel (a quantity varying in size between a cherry and a walnut) are sufficient to treat an area of ​​400-800 cm². After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. Caution: Use only for short treatment periods. The duration of treatment depends on the indication for use and the clinical response. The gel should not be used for more than 14 days without medical advice. Consult your doctor if symptoms persist or worsen after 7 days of treatment. \u003cb\u003eAdolescents aged 14 to 18:\u003c\/b\u003e Apply Voltaren Emulgel 2% gel 2 times a day on the area to be treated (preferably in the morning and evening), rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 2-4 g of Voltaren Emulgel 2% gel (a quantity varying in size between a cherry and a walnut) are sufficient to treat an area of ​​400-800 cm². After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. If this product is needed for more than 7 days to relieve pain or if symptoms worsen, consult a doctor. \u003cb\u003eChildren under 14 years:\u003c\/b\u003e Insufficient data are available on efficacy and safety in children and adolescents under 14 years of age (see section 4.3 Contraindications). Therefore, the use of Voltaren Emulgel 2% gel is contraindicated in children under 14 years of age. \u003cb\u003eElderly (over 65 years old)\u003c\/b\u003e The usual dosage for adults can be used.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e cannot be excluded if the preparation is used on large skin areas and for a prolonged period\u003ci\u003e.\u003c\/i\u003e \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e it must only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e it can be used with non-occlusive dressings, but must not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains 200 mg of propylene glycol per dose (4 g) equivalent to 50 mg\/g which may cause skin irritation. \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains butylated hydroxytoluene which may cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains pungent eucalyptus scent, an aroma which in turn contains benzyl alcohol, citronellol, coumarin, d-limonene, eugenol, geraniol, linalool which may cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects include mild, transient skin reactions at the application site. In very rare cases, allergic reactions may occur. Undesirable effects (Table 1) are listed below by organ, system\/system and MedDRA frequency. Frequencies are defined as: very common (≥ 1\/10) common (≥ 1\/100 to \u003c1\/10); uncommon (≥ 1\/1,000 to \u003c 1\/100); rare (≥ 1\/10,000 to \u003c 1\/1,000); very rare (\u003c 1\/10,000) not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioedema.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Dermatitis (including contact dermatitis), rash, erythema, eczema, pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction, allergic reactions.\u003c\/p\u003e\n\u003cp\u003eNot known: Burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of topical diclofenac makes overdose very unlikely; however side effects similar to those observed after an overdose of diclofenac tablets\u003ci\u003e,\u003c\/i\u003e can be expected just in case \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e is ingested (1 60 g tube contains the equivalent of 1.2 g of diclofenac sodium). In case of ingestion, which gives rise to significant systemic side effects, the general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Further treatment modalities, within the short term of ingestion, should take into account clinical indications or the recommendation of the poison control center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increases from less than 1% to approximately 1.5%. The risk is believed to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality; furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors had been administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e it must not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4 Special warnings and precautions for use).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":46369425260871,"sku":"034548154","price":17.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/novartis-farma-spa-voltaren-emulgel-gel-2-100-gr-farmacia-dottor-tili-1213792507.jpg?v=1767112290"},{"product_id":"transact-lat-10-cerotti-antidolorifici-flurbiprofene-40-mg","title":"Transact Lat 10 Pain Relief Patches Flurbiprofen 40 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTRANSACT Lat is indicated for the local symptomatic treatment of painful conditions affecting the musculoskeletal system.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA medicated plaster contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: Flurbiprofen 40.0 mg. For the full list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTartaric acid, purified water, titanium dioxide (E 171), kaolin, sodium caramellose, mint essence, glycerol, isopropyl myristate, sodium polyacrylate, polysorbate 80, sorbitan sesquioleate. Polyester support with protective polypropylene film, to be removed before use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance, or to any of the excipients listed in paragraph 6.1. Hypersensitivity to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). History of gastrointestinal bleeding or perforation related to previous NSAID treatment. Active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer, or gastrointestinal hemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Severe heart failure. Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). \u003ci\u003eElderly and patients with renal impairment\u003c\/i\u003e In elderly patients, particularly those with renal impairment, slow elimination of non-steroidal anti-inflammatory drugs is possible and, in such cases, Transact Lat should be administered with caution (see section 4.4). \u003ci\u003ePediatric population\u003c\/i\u003e TRANSACT Lat is not recommended in pediatric patients. \u003cu\u003eMethod of administration\u003c\/u\u003e TRANSACT Lat is for cutaneous use only. After having carefully washed and dried the painful area, grasp the two shorter sides of the TRANSACT Lat patch with both hands and pull slightly in the opposite direction as indicated by the arrows. This will cause the protective film in the central part of the patch to lift. Remove the protective film and apply the adhesive side directly to the skin. In the event that TRANSACT Lat must be applied to joints with greater mobility, such as the elbow or knee, it is advisable to use a retention bandage to be applied to the flexed joint. Apply only one medicated plaster at a time to the affected area every 12 hours. Dispose of the patch in safe conditions to avoid accidental ingestion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at a temperature not exceeding 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicated plaster must only be applied to intact skin, not to open wounds or lesions and must not be applied during a bath or shower. The medicated plaster must not come into contact with the eyes or be applied to mucous membranes or eyes. The medicated plaster must not be used with occlusive dressings. Application of the medicated plaster should be discontinued if a skin rash develops. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on gastrointestinal and cardiovascular risks). \u003cb\u003e \u003ci\u003e \u003cu\u003eGastrointestinal effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse events can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal events. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. The concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of aspirin or other drugs that may increase the risk of gastrointestinal events (see below and section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking Flurbiprofen, treatment should be discontinued. \u003cb\u003e \u003ci\u003e \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Adequate monitoring and appropriate instructions are necessary in patients with a history of hypertension and\/or mild to moderate congestive heart failure since, in association with treatment with NSAIDs, fluid retention and edema have been found. The product is contraindicated in patients with severe heart failure (see section 4.3). Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. \u003cb\u003e \u003ci\u003e \u003cu\u003eSkin reactions\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003e \u003ci\u003e \u003cu\u003eRespiratory reactions\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma. \u003cb\u003e \u003ci\u003e \u003cu\u003eHepatic impairment\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Caution is required in patients with hepatic impairment. There is a greater risk of gastro-intestinal bleeding and fluid retention. NSAIDs should be avoided in severe liver disease. \u003cb\u003e \u003ci\u003e \u003cu\u003eRenal impairment\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e NSAIDs should be avoided if possible or used with caution in patients with renal impairment; The lowest possible dosage should be used for the shortest time and renal function should be monitored. NSAIDs can cause kidney failure, especially in patients with pre-existing kidney problems. \u003cb\u003e \u003ci\u003e \u003cu\u003eOther Reactions\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Caution should be used when initiating treatment with NSAIDs such as flurbiprofen in patients with considerable dehydration. Particular caution must be taken when treating patients with severely reduced renal, cardiac or hepatic function as the use of NSAIDs can lead to deterioration of renal function. In such patients the dosage should be kept as low as possible and renal function should be monitored. Prolonged or repeated use of products for skin use can give rise to sensitization phenomena. In the presence of hypersensitivity reactions it is necessary to interrupt therapy. To avoid any phenomena of hypersensitivity or photosensitization, avoid exposure to direct sunlight, including the solarium, during treatment and in the following two weeks. \u003cb\u003e \u003ci\u003e \u003cu\u003eReduction in female fertility\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Long-term use of some NSAIDs is associated with reduced female fertility which is reversible by stopping treatment. \u003cb\u003e \u003ci\u003e \u003cu\u003eSLE and mixed connective tissue disease\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Aseptic meningitis has rarely been reported with NSAIDs. Patients with connective tissue diseases, such as systemic lupus erythematosus, may be particularly susceptible (see section 4.8). \u003cb\u003e \u003ci\u003e \u003cu\u003eElderly\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. \u003cb\u003eDiuretics, ACE inhibitors and angiotensin II antagonists\u003c\/b\u003e: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclooxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Flurbiprofen concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and on a periodic basis thereafter. \u003cb\u003eCardiac glycosides\u003c\/b\u003e: NSAIDs can exacerbate heart failure, reduce glomerular filtration rate and increase plasma levels of cardiac glycosides. \u003cb\u003eAnticoagulants, such as warfarin\u003c\/b\u003e: increased anticoagulant effect. \u003cb\u003eAspirin\u003c\/b\u003e: As with other NSAID-containing medicines, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects. \u003cb\u003eAnti-aggregating agents\u003c\/b\u003e: increased risk of gastrointestinal bleeding. \u003cb\u003eSelective serotonin reuptake inhibitors (SSRIs)\u003c\/b\u003e: increased risk of gastrointestinal bleeding. \u003cb\u003eLithium salts\u003c\/b\u003e: decrease in lithium elimination. \u003cb\u003eMethotrexate\u003c\/b\u003e: Caution is advised in case of concomitant administration of flurbiprofen and methotrexate as NSAIDs may increase methotrexate levels. \u003cb\u003eCyclosporine\u003c\/b\u003e: increased risk of nephrotoxicity with NSAIDs. \u003cb\u003eCorticosteroids\u003c\/b\u003e: increased risk of gastrointestinal ulcer or bleeding with NSAIDs. \u003cb\u003eCox-2 inhibitors and other NSAIDs\u003c\/b\u003e: Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects. \u003cb\u003eQuinolone antibiotics\u003c\/b\u003e: Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. \u003cb\u003eMifepristone\u003c\/b\u003e: NSAIDs should not be taken for 8-12 days after administration of mifepristone as NSAIDs may reduce the effects of mifepristone. \u003cb\u003eTacrolimus\u003c\/b\u003e: possible increased risk of nephrotoxicity in case of co-administration with NSAIDs. \u003cb\u003eZidovudine\u003c\/b\u003e: increased risk of blood toxicity in case of co-administration with NSAIDs. There is evidence of an increased risk of haemarthrosis and haematoma in haemophilia patients affected by HIV in simultaneous treatment with Zidovudine and other NSAIDs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse events that have been associated with Flurbiprofen are reported below, listed by systemic organ classification frequency. Frequencies are defined as: very common (≥1\/10), common, (≥1\/100 to \u003c1\/10), uncommon (≥1\/1000 to \u003c1\/100), rare (≥1\/10,000 to \u003c1\/1000), very rare (\u003c1\/10,000) and not known (impossible to estimate from the available data). Within each frequency group, adverse events are reported in order of decreasing severity.\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system. - Frequency: Not known:. Side effects: thrombocytopenia, aplastic anemia, agranulocytosis.\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system. - Frequency: Not known:. Side effects: neutropenia, hemolytic anemia.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders. - Frequency: Not known:. Side effects: anaphylactic reaction, angioedema, hypersensitivity.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders. - Frequency: Not known:. Side effects: depression.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders. - Frequency: Not known:. Side effects: dizziness, cerebrovascular accidents, optic neuritis, migraine, paraesthesia, tingling, dysesthesia, confusion, hallucination, dizziness, drowsiness, aseptic meningitis (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eEye pathologies. - Frequency: Not known:. Side effects: visual impairment.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders. - Frequency: Not known:. Side effects: tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac diseases. - Frequency: Not known:. Side effects: edema, heart failure.\u003c\/p\u003e\n\u003cp\u003eVascular pathologies. - Frequency: Not known:. Side effects: hypertension, arterial thromboembolic events.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal diseases. - Frequency: Not known:. Side effects: respiratory tract reactivity (asthma, bronchospasm and dyspnoea).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders. - Frequency: Very rare:. Side effects: pancreatitis.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders. - Frequency: Not known:. Side effects: abdominal pain, dyspepsia, nausea, vomiting, diarrhea, melena, hematemesis, ulcerative stomatitis, peptic ulcer, perforated ulcer, hemorrhagic ulcer, gastritis, gastrointestinal hemorrhage, flatulence, constipation, exacerbation of colitis, Crohn's disease.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue. - Frequency: Very rare:. Side effects: bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme).\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue. - Frequency: Not known:. Side effects: rash, itching, urticaria, erythema, purpura, eruptions.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders. - Frequency: Not known:. Side effects: nephrotoxicity (including interstitial nephritis, nephrotic syndrome), renal failure.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site. - Frequency: Not known:. Side effects: malaise, fatigue.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazionireazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003eSymptoms\u003c\/u\u003e \u003c\/b\u003e Symptoms of overdose may include nausea, vomiting, abdominal pain, and gastrointestinal irritation. \u003cu\u003e \u003cstrong\u003eTreatment\u003c\/strong\u003e \u003c\/u\u003e There is no specific antidote for flurbiprofen. Supportive measures appropriate for the management of overdose of non-steroidal anti-inflammatory drugs should be implemented, including, if necessary, correction of the serum electrolyte picture.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, Flurbiprofen should not be administered unless strictly necessary. If Flurbiprofen is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: • Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); • Renal dysfunction, which may progress to renal failure with oligohydroamnios; the mother and the newborn, at the end of pregnancy, to: • Possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; • Inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, Flurbiprofen is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e Flurbiprofen is excreted in breast milk; however the amount excreted is only a small fraction of the maternal dose. The administration of flurbiprofen is not recommended in breastfeeding mothers. \u003cu\u003eFertility\u003c\/u\u003e Long-term use of some NSAIDs is associated with reduced female fertility which is reversible by stopping treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTRANSACT Lat does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Recordati","offers":[{"title":"Default Title","offer_id":46488677974343,"sku":"028741015","price":24.61,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/recordati-spa-transact-lat-10-cerotti-antidolorifici-flurbiprofene-40-mg-farmacia-dottor-tili-1213792492.webp?v=1767112477"},{"product_id":"flector-180mg-5-cerotti-medicati","title":"Flector 180mg 5 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of: • Joints; • Muscles; • Tendons; • Ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA 180 mg medicated plaster contains: • active ingredient: diclofenac hydroxyethylpyrrolidine 180 mg (equal to 140 mg of sodium diclofenac); • excipients with known effects: propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, perfume in turn containing amyl cinnamal, amyl cinnamal alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGelatin, polyvinylpyrrolidone, sorbitol solution 70%, kaolin, titanium dioxide, propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, disodium edetate, tartaric acid, dihydroxyaluminium aminoacetate, sodium carboxymethylcellulose, sodium polyacrylate, 1-3-butylene glycol, polysorbate 80, perfume, purified water, synthetic felt, plastic film.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to acetylsalicylic acid or to other analgesics or other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients listed in paragraph 6.1. • Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). • Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns, or wounds. • Third trimester of pregnancy (see section 4.6). • Patients with active peptic ulcer. \u003ci\u003e \u003cu\u003eChildren and adolescents\u003c\/u\u003e \u003c\/i\u003e: Use in children and adolescents under 16 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. \u003cu\u003eDosage\u003c\/u\u003e: The medicine should only be applied to intact, healthy skin and should not be applied when bathing or showering. The diclofenac medicated plaster must be used for the shortest time possible in relation to the indication of use. \u003ci\u003eAdults\u003c\/i\u003e: The usual dosage regimen is 1 or 2 patches per day (one application every 12 or 24 hours) for a period of up to 14 days. Advise the patient to consult their doctor if they do not experience improvement following the recommended treatment period (see section 4.4). \u003ci\u003ePediatric population\u003c\/i\u003e. \u003ci\u003eChildren and adolescents under 16 years of age\u003c\/i\u003e: the use of this medicated plaster is not recommended because insufficient data are available to evaluate the safety and efficacy of the medicine (see section 4.3). \u003ci\u003eIn adolescents aged 16 years and older\u003c\/i\u003e: If the medicine is needed for a treatment period longer than 7 days for pain relief or if symptoms worsen, a re-evaluation is necessary. Advise the patient or the adolescent's relatives to consult the doctor. \u003ci\u003eElderly\u003c\/i\u003e: This medicine should be used with caution in elderly patients as they are more predisposed to side effects (see section 4.4). \u003ci\u003ePatients with hepatic or renal insufficiency\u003c\/i\u003e: For the use of diclofenac medicated plasters in patients with hepatic or renal insufficiency, consult section 4.4. \u003cu\u003eMethod of administration\u003c\/u\u003e: Cut the bag containing the medicated plaster as indicated. Take out a medicated plaster, remove the plastic film used to protect the adhesive surface and apply the plaster to the joint or painful surface. If necessary, the patch can be held in place using an elastic band (the package contains a tubular net). Close the envelope carefully. The patch must be used entirely. Avoid contact with eyes or mucous membranes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo particular storage conditions are necessary.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf diclofenac medicated plasters are used on large skin surfaces and for a prolonged period of time, the possibility of systemic adverse events cannot be excluded (see the Summary of Product Characteristics of the systemic formulations of diclofenac). The medicated plaster must be applied only to intact and healthy skin and must not be applied to damaged skin or open wounds. The patches should not come into contact with the eyes or mucous membranes. Asthmatic patients with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to treatment with NSAIDs more often than other patients. The use, especially if prolonged, of this as well as other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Although systemic absorption is minimal, the use of FLECTOR, as with any drug that inhibits prostaglandin synthesis and cyclooxygenase, is not recommended in women intending to become pregnant. The administration of FLECTOR should be suspended in women who have fertility problems or who are undergoing fertility investigations. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. • Do not use with an occlusive dressing that does not allow air to pass through. • Treatment should be stopped immediately if a skin rash develops after applying the medicated plaster. • Do not simultaneously administer topically or systemically another medicinal product containing diclofenac or other NSAIDs. • Although systemic effects should be low, the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or bleeding diathesis. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients who are more predisposed to side effects. • Patients should be advised not to expose themselves to direct sunlight or sun lamps for approximately one day after removal of the medicated plaster to reduce the risk of photosensitivity. \u003cu\u003eImportant information about some excipients\u003c\/u\u003e. FLECTOR contains: - methyl parahydroxybenzoate, propyl parahydroxybenzoate: may cause allergic reactions (even delayed); - 420 mg of propylene glycol in each patch: may cause skin irritation; - an aroma (perfume) in turn containing amyl cinnamal, amyl cinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate: may cause reactions allergic\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible. Clinical investigations carried out with FLECTOR medicated plaster used in conjunction with other steroidal and non-steroidal anti-inflammatory drugs (salazopyrin, hydroxyquinoline, etc.) have not highlighted any interaction phenomena. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs is not recommended (see section 4.8).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); not known: cannot be estimated from available data. \u003cb\u003eTable 1 \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003eFollowing applications for long periods of time on large skin surfaces, due to the amount of active ingredient that is absorbed, the appearance of systemic undesirable effects, especially at the gastrointestinal level, cannot be excluded. The use of the product in association with other drugs containing diclofenac can give rise to phenomena of hypersensitivity to light, skin rash with the formation of vesicles, eczema, erythema and, in rare cases, severe skin reactions (severe Stevens-Johnson, Lyell syndrome) (see section 4.5). \u003cu\u003eReporting of suspected adverse reactions.\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported with diclofenac medicated plasters. Should systemic side effects occur due to incorrect use or accidental overdose (e.g. in children) with the product, the general supportive measures to be taken in case of intoxication with non-steroidal anti-inflammatory drugs are recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e: The systemic concentration of diclofenac, compared to oral formulations, is lower after topical administration. Referring to the experience of treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e: Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of diclofenac medicated plasters, no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, diclofenac medicated plasters should not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe application of diclofenac medicated plasters does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Ibsa","offers":[{"title":"Default Title","offer_id":51131188150599,"sku":"027757032","price":15.72,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ibsa-farmaceutici-italia-srl-flector-180mg-5-cerotti-medicati-farmacia-dottor-tili-1213792401.jpg?v=1767132569"},{"product_id":"flector-180mg-10-cerotti-medicati","title":"Flector 180mg 10 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of: • Joints; • Muscles; • Tendons; • Ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA 180 mg medicated plaster contains: • active ingredient: diclofenac hydroxyethylpyrrolidine 180 mg (equal to 140 mg of sodium diclofenac); • excipients with known effects: propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, perfume in turn containing amyl cinnamal, amyl cinnamal alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGelatin, polyvinylpyrrolidone, sorbitol solution 70%, kaolin, titanium dioxide, propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, disodium edetate, tartaric acid, dihydroxyaluminium aminoacetate, sodium carboxymethylcellulose, sodium polyacrylate, 1-3-butylene glycol, polysorbate 80, perfume, purified water, synthetic felt, plastic film.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to acetylsalicylic acid or to other analgesics or other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients listed in paragraph 6.1. • Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). • Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns, or wounds. • Third trimester of pregnancy (see section 4.6). • Patients with active peptic ulcer. \u003ci\u003e \u003cu\u003eChildren and adolescents\u003c\/u\u003e \u003c\/i\u003e: Use in children and adolescents under 16 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. \u003cu\u003eDosage\u003c\/u\u003e: The medicine should only be applied to intact, healthy skin and should not be applied when bathing or showering. The diclofenac medicated plaster must be used for the shortest time possible in relation to the indication of use. \u003ci\u003eAdults\u003c\/i\u003e: The usual dosage regimen is 1 or 2 patches per day (one application every 12 or 24 hours) for a period of up to 14 days. Advise the patient to consult their doctor if they do not experience improvement following the recommended treatment period (see section 4.4). \u003ci\u003ePediatric population\u003c\/i\u003e. \u003ci\u003eChildren and adolescents under 16 years of age\u003c\/i\u003e: the use of this medicated plaster is not recommended because insufficient data are available to evaluate the safety and efficacy of the medicine (see section 4.3). \u003ci\u003eIn adolescents aged 16 years and older\u003c\/i\u003e: If the medicine is needed for a treatment period longer than 7 days for pain relief or if symptoms worsen, a re-evaluation is necessary. Advise the patient or the adolescent's relatives to consult the doctor. \u003ci\u003eElderly\u003c\/i\u003e: This medicine should be used with caution in elderly patients as they are more predisposed to side effects (see section 4.4). \u003ci\u003ePatients with hepatic or renal insufficiency\u003c\/i\u003e: For the use of diclofenac medicated plasters in patients with hepatic or renal insufficiency, consult section 4.4. \u003cu\u003eMethod of administration\u003c\/u\u003e: Cut the bag containing the medicated plaster as indicated. Take out a medicated plaster, remove the plastic film used to protect the adhesive surface and apply the plaster to the joint or painful surface. If necessary, the patch can be held in place using an elastic band (the package contains a tubular net). Close the envelope carefully. The patch must be used entirely. Avoid contact with eyes or mucous membranes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo particular storage conditions are necessary.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf diclofenac medicated plasters are used on large skin surfaces and for a prolonged period of time, the possibility of systemic adverse events cannot be excluded (see the Summary of Product Characteristics of the systemic formulations of diclofenac). The medicated plaster must be applied only to intact and healthy skin and must not be applied to damaged skin or open wounds. The patches should not come into contact with the eyes or mucous membranes. Asthmatic patients with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to treatment with NSAIDs more often than other patients. The use, especially if prolonged, of this as well as other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Although systemic absorption is minimal, the use of FLECTOR, as with any drug that inhibits prostaglandin synthesis and cyclooxygenase, is not recommended in women intending to become pregnant. The administration of FLECTOR should be suspended in women who have fertility problems or who are undergoing fertility investigations. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. • Do not use with an occlusive dressing that does not allow air to pass through. • Treatment should be stopped immediately if a skin rash develops after applying the medicated plaster. • Do not simultaneously administer topically or systemically another medicinal product containing diclofenac or other NSAIDs. • Although systemic effects should be low, the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or bleeding diathesis. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients who are more predisposed to side effects. • Patients should be advised not to expose themselves to direct sunlight or sun lamps for approximately one day after removal of the medicated plaster to reduce the risk of photosensitivity. \u003cu\u003eImportant information about some excipients\u003c\/u\u003e. FLECTOR contains: - methyl parahydroxybenzoate, propyl parahydroxybenzoate: may cause allergic reactions (even delayed); - 420 mg of propylene glycol in each patch: may cause skin irritation; - an aroma (perfume) in turn containing amyl cinnamal, amyl cinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate: may cause reactions allergic\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible. Clinical investigations carried out with FLECTOR medicated plaster used in conjunction with other steroidal and non-steroidal anti-inflammatory drugs (salazopyrin, hydroxyquinoline, etc.) have not highlighted any interaction phenomena. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs is not recommended (see section 4.8).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); not known: cannot be estimated from available data. \u003cb\u003eTable 1 \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003eFollowing applications for long periods of time on large skin surfaces, due to the amount of active ingredient that is absorbed, the appearance of systemic undesirable effects, especially at the gastrointestinal level, cannot be excluded. The use of the product in association with other drugs containing diclofenac can give rise to phenomena of hypersensitivity to light, skin rash with the formation of vesicles, eczema, erythema and, in rare cases, severe skin reactions (severe Stevens-Johnson, Lyell syndrome) (see section 4.5). \u003cu\u003eReporting of suspected adverse reactions.\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported with diclofenac medicated plasters. Should systemic side effects occur due to incorrect use or accidental overdose (e.g. in children) with the product, the general supportive measures to be taken in case of intoxication with non-steroidal anti-inflammatory drugs are recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e: The systemic concentration of diclofenac, compared to oral formulations, is lower after topical administration. Referring to the experience of treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e: Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of diclofenac medicated plasters, no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, diclofenac medicated plasters should not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe application of diclofenac medicated plasters does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Ibsa","offers":[{"title":"Default Title","offer_id":51131235336519,"sku":"027757044","price":22.23,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ibsa-farmaceutici-italia-srl-flector-180mg-10-cerotti-medicati-farmacia-dottor-tili-1213792316.jpg?v=1767143369"},{"product_id":"voltaren-emulgel-gel-2-180-gr","title":"Voltaren Emulgel Gel 2% 180 Gr","description":"\u003cp\u003eVoltaren Emulgel Gel \u003cstrong\u003epainkiller and anti-inflammatory\u003c\/strong\u003e for \u003cstrong\u003emuscle and joint pain\u003c\/strong\u003e based on Diclofenac (2%). Voltaren Emulgel is a local treatment of \u003cstrong\u003epainful and inflammatory states\u003c\/strong\u003e: of a rheumatic or traumatic nature of the joints, such as \u003cstrong\u003eosteoarthritis and arthritis\u003c\/strong\u003e; of the muscles, in case of \u003cstrong\u003econtractures or injuries\u003c\/strong\u003e; of tendons and ligaments, in the presence of \u003cstrong\u003etendinitis\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Voltaren Emulgel Gel 2% 180 Gr used? What is it for?\u003c\/h3\u003e\u003cp dir=\"\"\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons and ligaments (such as tendonitis).\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Voltaren Emulgel Gel 2% 180 Gr?\u003c\/h3\u003e\u003cp dir=\"\"\u003e100 g of Voltaren Emulgel contain 2.32 g of diclofenac diethylammonium, equivalent to 2 g of diclofenac sodium. Excipients with known effects: propylene glycol (50 mg\/g of gel), butylated hydroxytoluene (0.2 mg\/g of gel), pungent eucalyptus perfume. For the full list of excipients, see section 6.1.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp dir=\"\"\u003eButylated hydroxytoluene, carbomers, cocoyl caprylocaprate, diethylamine, isopropyl alcohol, liquid paraffin, macrogol cetostearyl ether, oleic alcohol, propylene glycol, pungent eucalyptus perfume, purified water.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow is Voltaren Emulgel Gel 2% 180 Gr taken?\u003c\/h3\u003e\u003cp dir=\"\"\u003eFor cutaneous use. Adults over 18 years of age, Voltaren Emulgel 2% gel provides pain relief for up to 12 hours: apply Voltaren Emulgel 2% gel 2 times a day on the area to be treated (preferably in the morning and evening), rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 2-4 g of Voltaren Emulgel 2% gel (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of ​​400-800 cm^2. After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. Warning: use only for short treatment periods. The duration of treatment depends on the indication for use and the clinical response. The gel should not be used for more than 14 days without medical advice. Consult your doctor if symptoms persist or worsen after 7 days of treatment. Adolescents aged 14 to 18: apply Voltaren Emulgel 2% gel 2 times a day on the area to be treated (preferably in the morning and evening), rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 2-4 g of Voltaren Emulgel 2% gel (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of ​​400-800 cm^2. After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. If this product is needed for more than 7 days to relieve pain or if symptoms worsen, consult a doctor. Children under 14 years: Insufficient data are available on the efficacy and safety of children and adolescents under 14 years (see section 4.3 Contraindications). Therefore, the use of Voltaren Emulgel 2% gel is contraindicated in children under 14 years of age. Elderly (over 65 years): the usual dosage for adults can be used.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Voltaren Emulgel Gel 2% 180 Gr not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp dir=\"\"\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1; history of asthma, angioedema, urticaria or acute rhinitis following the intake of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs); during the third trimester of pregnancy; use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp dir=\"\"\u003eSide effects include mild, transient skin reactions at the application site. In very rare cases, allergic reactions may occur. Side effects are listed below by organ, system\/system and MedDRA frequency. Frequencies are defined as: very common (\u003e= 1\/10) common (\u003e= 1\/100 to \u003c1\/10); uncommon (\u003e= 1\/1,000 to \u003c 1\/100); rare (\u003e= 1\/10,000 to \u003c 1\/1,000); very rare (\u003c 1\/10,000) not known (frequency cannot be estimated from the available data). Infections and infestations. Very rare: rash with pustules. Immune system disorders. Very rare: hypersensitivity (including urticaria), angioedema. Respiratory, thoracic and mediastinal disorders. Very rare: asthma. Pathologies of the skin and subcutaneous tissue. Common: dermatitis (including contact dermatitis), rash, erythema, eczema, pruritus; rare: bullous dermatitis; very rare: photosensitivity reaction, allergic reactions; not known: burning sensation at the application site, dry skin. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can modify the effect of Voltaren Emulgel Gel 2% 180 Gr?\u003c\/h3\u003e\u003cp dir=\"\"\u003eSince the systemic absorption of diclofenac following topical application is very low, interactions are very unlikely.\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Voltaren Emulgel Gel 2% 180 Gr be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp dir=\"\"\u003ePregnancy: the systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: the inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increases from less than 1%, up to approximately 1.5%. The risk is believed to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality; furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors had been administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Diclofenac is contraindicated during the third trimester of pregnancy. Breastfeeding: Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of Voltaren Emulgel 2% no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, Voltaren Emulgel 2% must not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4 Special warnings and precautions for use).\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Voltaren Emulgel Gel 2% 180 Gr?\u003c\/h3\u003e\u003cp dir=\"\"\u003eThe possibility of systemic adverse events with the application of Voltaren Emulgel 2% cannot be excluded if the preparation is used on large skin areas and for a prolonged period. Voltaren Emulgel 2% must be applied only to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. Voltaren Emulgel 2% can be used with non-occlusive dressings, but must not be used with an occlusive dressing that does not allow air to pass through. Important information about some excipients: Voltaren Emulgel 2% gel contains 200 mg of propylene glycol per dose (4 g) equivalent to 50 mg\/g which may cause skin irritation. Voltaren Emulgel 2% gel contains butylated hydroxytoluene which may cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. Voltaren Emulgel 2% gel contains pungent eucalyptus scent, an aroma which in turn contains benzyl alcohol, citronellol, coumarin, d-limonene, eugenol, geraniol, linalool which may cause allergic reactions.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Voltaren Emulgel Gel 2% 180 Gr stored?\u003c\/h3\u003e\u003cp dir=\"\"\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Voltaren Emulgel Gel 2% 180 Gr?\u003c\/h3\u003e\u003cp\u003e180 gr\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":51131285078343,"sku":"034548230","price":27.08,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/novartis-farma-spa-voltaren-emulgel-gel-2-180-gr-farmacia-dottor-tili-1213792236.jpg?v=1767133870"},{"product_id":"reparil-2-5-gel-40g","title":"Reparil 2% + 5% gel 40g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMinor traumatology\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eREPARIL 1% + 5% gel\u003c\/i\u003e 100 g of gel contains: \u003ci\u003eActive ingredients:\u003c\/i\u003e Escin 1 g Diethylamine salicylate 5 g \u003ci\u003eREPARIL 2% + 5% gel\u003c\/i\u003e 100 g of gel contains: \u003ci\u003eActive ingredients:\u003c\/i\u003e Escin 2 g Diethylamine salicylate 5 g Excipients with known effects Lavender oil and bitter orange flower oil with d-limonene, farinasol and linalool. For the full list of excipients see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLavender essence, bitter orange flower essence, carbomers, macrogol 6 glycerol caprylocaprate, disodium edetate, trometamol, isopropyl alcohol, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients. REPARIL should not be used on open lesions (wounds), mucous membranes and skin areas treated with radiation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAdults and adolescents (12-18 years): \u003c\/b\u003e Apply and spread a thin layer of REPARIL on the skin of the area to be treated 1 to 3 times a day. Apply the gel directly to the affected area. After each application, wash your hands thoroughly. \u003cb\u003eChildren under 12 years:\u003c\/b\u003e The safety and effectiveness of REPARIL in children under 12 years of age have not been established. There is no data available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere is no risk of addiction and dependence. Since it is a preparation for topical applications, its use must be exclusively external. The use, especially prolonged, of products for topical use can give rise to sensitization phenomena. This medicine contains lavender oil and bitter orange blossom oil with d-limonene, farfalle and linalool as fragrances. These substances can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo interactions with other medicinal products have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn rare cases, hypersensitivity reactions such as redness, scaling and dehydration of the skin may appear. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of pregnancy and breastfeeding, it is not recommended to use REPARIL unless under strict medical supervision. However, prolonged use (maximum 3 weeks) of the product on large skin areas during pregnancy and use on the breasts during breastfeeding should be avoided.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eREPARIL does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Viatris Healthcare","offers":[{"title":"Default Title","offer_id":51131314929991,"sku":"036397026","price":10.23,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/viatris-healthcare-limited-reparil-2-5-gel-40g-farmacia-dottor-tili-1213792116.jpg?v=1767135988"},{"product_id":"lasonil-antidolore-10-gel-50g","title":"Lasonil painkiller 10% gel 50g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of bruises, sprains, myalgia, muscle strains, stiff neck.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of gel contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: Ibuprofen lysine salt 10 g \u003cu\u003eExcipients\u003c\/u\u003e: Sodium methyl paraoxybenzoate, sodium ethyl paraoxybenzate. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIsopropanol, hydroxyethylcellulose, sodium methyl paraoxybenzoate, sodium ethyl paraoxybenzoate, glycerol, lavender essence, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients. Due to the possibility of cross-sensitization, the medicine must not be administered to patients in whom acetylsalicylic acid or other non-steroidal anti-inflammatory drugs have caused asthma, rhinitis, urticaria or other allergic manifestations. - Pregnancy. - Breastfeeding - Children and adolescents under 14 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e2-4 applications per day on the painful part. Elderly patients should stick to the minimum dosages indicated above. Apply a thin layer of gel on the area to be treated with a light massage. Use the medicine for the shortest period possible. Wash your hands carefully and thoroughly after application.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special instructions\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt is advisable to avoid applying LASONIL ANTIDOLORE to open wounds or skin lesions. The use of LASONIL ANTIDOLORE, like any drug that inhibits the synthesis of prostaglandins and cyclooxygenase, is not recommended in women who intend to become pregnant. The administration of LASONIL ANTIDOLORE must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use of LASONIL ANTIDOLORE, especially if prolonged, can give rise to local sensitization phenomena: at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity, interrupt treatment and adopt adequate therapeutic measures. To avoid more serious hypersensitivity or photosensitization phenomena, the patient must not expose himself to direct sunlight, including the solarium, during treatment and in the following two weeks (see section 4.8). Do not use LASONIL ANTIDOLORE together with another NSAID or, in any case, do not use more than one NSAID at a time. Severe skin reactions Severe skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at higher risk in the early stages of therapy: the onset of the reaction occurs in most cases within the first month of treatment. Acute generalized exanthematous pustulosis (PEAG) has been reported in connection with ibuprofen-containing medicinal products. Ibuprofen should be discontinued at the first appearance of signs and symptoms of severe skin reactions, such as rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003eImportant information about some excipients of LASONIL ANTIDOLORE\u003c\/b\u003e: the medicine contains sodium methyl para-oxybenzoate and sodium ethyl para-oxybenzoate which may cause allergic reactions (possibly delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe paucity of data and the uncertainties relating to their application to the clinical situation do not allow definitive conclusions to be drawn on possible interactions with other drugs for the continuous use of ibuprofen; no clinically relevant interactions have been found with the occasional use of ibuprofen. Bear in mind, in any case, that Ibuprofen can increase the effects of anticoagulants such as warfarin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Skin reactions with erythema, itching, irritation, sensation of heat or burning and contact dermatitis have been reported with some non-steroidal anti-inflammatory drugs derived from propionic acid for local or transdermal use. Some cases of bullous eruptions of varying severity, including Stevens Johnson syndrome, and toxic epidermal necrolysis (very rarely) have also been reported. Frequency not known: - Acute generalized exanthematous pustulosis (PEAG) (see section 4.4) - Photosensitivity reactions (see section 4.4) \u003cb\u003e \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of LASONIL ANTIDOLORE is contraindicated during pregnancy and breastfeeding. Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo\/fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the genetic organ period. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose • the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; • the mother and newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":51131316797767,"sku":"042154017","price":9.63,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-lasonil-antidolore-10-gel-50g-farmacia-dottor-tili-1213792110.jpg?v=1767136111"},{"product_id":"momendol-10-gel-50g","title":"Momendol 10% gel 50g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMomendol 10% gel is indicated in adults and children over 12 years of age for the local treatment of pain in muscular and joint diseases such as myalgia, lumbago, stiff neck, bursitis, tendinitis, tenosynovitis, periarthritis, muscle strains, contusions, hematomas. Adjuvant of orthopedic and rehabilitation therapies.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e1 g contains: Active ingredient: 100 mg of naproxen (10% w\/w). Excipients with known effects: D-Limonene flavour. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIsopropyl alcohol, Trolamine, Glycerol, Hydroxyethyl cellulose, Sodium hydroxide, Perfume containing menthol and eucalyptol, Purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e: Spread Momendol 10% gel on the site of pain 2 times a day. The duration of treatment should not exceed 7 days. \u003ci\u003ePediatric population\u003c\/i\u003e: Momendol 10% gel is contraindicated in children under 12 years. The safety and effectiveness of Momendol 10% gel in children under 12 years have not yet been established. There is no data available. \u003cu\u003eMethod of administration\u003c\/u\u003e: \u003cu\u003eSpread Momendol 10% gel on the site of pain and massage lightly until completely absorbed.\u003c\/u\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine does not require any particular storage temperature. Store in the original packaging with the cap closed to protect the medicine from light and evaporation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid using the gel on eyes, mucous membranes, wounds and\/or skin lesions. The amount of active ingredient absorbed through the skin does not reach blood concentrations such as to expose one to the risk of side effects or such as to make the warnings relating to systemic administration of the drug applicable. However, we do not recommend the use of Momendol 10% gel to patients in whom acetylsalicylic acid and\/or other NSAIDs induce allergic reactions and we also do not recommend its use in patients with active allergic reactions or a positive history. To prevent any phenomena of hypersensitivity or photosensitization, avoid exposure to direct sunlight, including the solarium, during treatment and in the following two weeks. Stop treatment if skin rashes or irritation occur. This medicine contains a fragrance with D-Limonene. D-Limonene can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies have been carried out d\u003cb\u003e’\u003c\/b\u003e interaction. The product is poorly absorbed at a systemic level therefore interactions with other drugs are unlikely, although they cannot be excluded.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following are the side effects organized according to the MedDRA System Organ classification. The frequency is defined as follows: very common (≥1\/10), common (≥1\/100 to \u003c1\/10), uncommon (≥1\/1000 to \u003c1\/100), rare (≥1\/10,000 to \u003c1\/1000), very rare (\u003c1\/10,000), not known (cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue (1).\u003c\/p\u003e\n\u003cp\u003eNot known - UNDESIRABLE EFFECT: Erythema, Pruritus, Skin irritation, Burning sensation of the skin, Contact dermatitis, Bullous rash, Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - SIDE EFFECT: Sensitization (2).\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eNot known - SIDE EFFECT: Sensation of heat.\u003c\/p\u003e\n\u003cp\u003e\u003csup\u003e1)\u003c\/sup\u003e Adverse skin reactions have been reported with some non-steroidal anti-inflammatory drugs for cutaneous or transdermal use, derivatives of propionic acid. \u003csup\u003e2)\u003c\/sup\u003e The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case, suspend treatment and adopt suitable therapeutic measures. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo case of overdose has been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe risk of harmful effects on the fetus and\/or child is not excluded. Therefore, during pregnancy and\/or breastfeeding Momendol gel must be used according to the doctor's judgment and when strictly necessary. Momendol gel should not be used in the third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMomendol 10% gel does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Angelini Pharma","offers":[{"title":"Default Title","offer_id":51131323023687,"sku":"025829197","price":11.07,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-momendol-10-gel-50g-farmacia-dottor-tili-1213792096.jpg?v=1767136332"},{"product_id":"lasonil-antidolore-10-gel-120gr","title":"Lasonil painkiller 10% gel 120gr","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of bruises, sprains, myalgia, muscle strains, stiff neck.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of gel contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: Ibuprofen lysine salt 10 g \u003cu\u003eExcipients\u003c\/u\u003e: Sodium methyl paraoxybenzoate, sodium ethyl paraoxybenzate. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIsopropanol, hydroxyethylcellulose, sodium methyl paraoxybenzoate, sodium ethyl paraoxybenzoate, glycerol, lavender essence, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients. Due to the possibility of cross-sensitization, the medicine must not be administered to patients in whom acetylsalicylic acid or other non-steroidal anti-inflammatory drugs have caused asthma, rhinitis, urticaria or other allergic manifestations. - Pregnancy. - Breastfeeding - Children and adolescents under 14 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e2-4 applications per day on the painful part. Elderly patients should stick to the minimum dosages indicated above. Apply a thin layer of gel on the area to be treated with a light massage. Use the medicine for the shortest period possible. Wash your hands carefully and thoroughly after application.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special instructions\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt is advisable to avoid applying LASONIL ANTIDOLORE to open wounds or skin lesions. The use of LASONIL ANTIDOLORE, like any drug that inhibits the synthesis of prostaglandins and cyclooxygenase, is not recommended in women who intend to become pregnant. The administration of LASONIL ANTIDOLORE must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use of LASONIL ANTIDOLORE, especially if prolonged, can give rise to local sensitization phenomena: at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity, interrupt treatment and adopt adequate therapeutic measures. To avoid more serious hypersensitivity or photosensitization phenomena, the patient must not expose himself to direct sunlight, including the solarium, during treatment and in the following two weeks (see section 4.8). Do not use LASONIL ANTIDOLORE together with another NSAID or, in any case, do not use more than one NSAID at a time. Severe skin reactions Severe skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at higher risk in the early stages of therapy: the onset of the reaction occurs in most cases within the first month of treatment. Acute generalized exanthematous pustulosis (PEAG) has been reported in connection with ibuprofen-containing medicinal products. Ibuprofen should be discontinued at the first appearance of signs and symptoms of severe skin reactions, such as rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003eImportant information about some excipients of LASONIL ANTIDOLORE\u003c\/b\u003e: the medicine contains sodium methyl para-oxybenzoate and sodium ethyl para-oxybenzoate which may cause allergic reactions (possibly delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe paucity of data and the uncertainties relating to their application to the clinical situation do not allow definitive conclusions to be drawn on possible interactions with other drugs for the continuous use of ibuprofen; no clinically relevant interactions have been found with the occasional use of ibuprofen. Bear in mind, in any case, that Ibuprofen can increase the effects of anticoagulants such as warfarin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Skin reactions with erythema, itching, irritation, sensation of heat or burning and contact dermatitis have been reported with some non-steroidal anti-inflammatory drugs derived from propionic acid for local or transdermal use. Some cases of bullous eruptions of varying severity, including Stevens Johnson syndrome, and toxic epidermal necrolysis (very rarely) have also been reported. Frequency not known: - Acute generalized exanthematous pustulosis (PEAG) (see section 4.4) - Photosensitivity reactions (see section 4.4) \u003cb\u003e \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of LASONIL ANTIDOLORE is contraindicated during pregnancy and breastfeeding. Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo\/fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the genetic organ period. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose • the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; • the mother and newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":51131332526407,"sku":"042154029","price":13.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-lasonil-antidolore-10-gel-120gr-farmacia-dottor-tili-1213792064.jpg?v=1767137147"},{"product_id":"dicloreum-antinfiammatorio-locale-3-schiuma-cutanea-50g","title":"Dicloreum local anti-inflammatory 3% skin foam 50g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e100 g of Skin Foam contain\u003c\/i\u003e: \u003ci\u003eActive ingredient\u003c\/i\u003e: Diclofenac 3 g Excipients with known effects: potassium sorbate 0.1 g, benzyl alcohol 0.5 g and mint\/eucalyptus fragrance (geraniol, limonene and linalool) 1 g. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSodium hydroxide, macroglycerols caprylocaprates, phospholipon 80 H, polysorbate 80, benzyl alcohol, potassium sorbate, disodium phosphate dodecahydrate, tocopherol acetate, mint\/eucalyptus fragrance, purified water. \u003ci\u003eEach pressurized container (50 g) contains\u003c\/i\u003e: 47.5 g of solution and 2.5 g of propellant (isobutane, n-butane, propane).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e§ Hypersensitivity to diclofenac, to any of the excipients, to acetylsalicylic acid and other non-steroidal anti-inflammatory drugs, as well as to isopropanol. § Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs) and isopropanol. § Third trimester of pregnancy (see section 4.6 \u003ci\u003eFertility, pregnancy and breastfeeding\u003c\/i\u003e). § Children and adolescents under 14 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAdults over 18 years:\u003c\/b\u003e Apply LOCAL ANTI-INFLAMMATORY DICLOREUM 1-3 times a day or according to medical prescription. For each application, spray a circular mass of foam 3-5 centimeters in diameter (equal to approximately 0.75-1.5 grams in weight) onto the palm of your hand, depending on the size of the area to be treated, massaging delicately until completely absorbed. In case of iontophoresis treatment, the product must be applied to the negative pole. LOCAL ANTI-INFLAMMATORY DICLOREUM can also be used in combination with ultrasound therapy. After application, wash your hands, otherwise they will also be treated with skin foam. Warning: use only for short treatment periods. \u003cb\u003eAdolescents aged 14 to 18:\u003c\/b\u003e Apply LOCAL ANTI-INFLAMMATORY DICLOREUM 1-3 times a day or according to medical prescription. For each application, spray a circular mass of foam 3-5 centimeters in diameter (equal to approximately 0.75-1.5 grams in weight) onto the palm of your hand, depending on the size of the area to be treated, massaging delicately until completely absorbed. In case of iontophoresis treatment, the product must be applied to the negative pole. LOCAL ANTI-INFLAMMATORY DICLOREUM can also be used in combination with ultrasound therapy. After application, wash your hands, otherwise they will also be treated with skin foam. If this medicine is needed for more than 7 days to relieve pain or if symptoms worsen, consult your doctor. \u003cb\u003eChildren and adolescents under 14 years: \u003c\/b\u003e Insufficient data are available on efficacy and safety in children and adolescents under 14 years (see also section 4.3 Contraindications). Therefore, the use of DICLOREUM LOCAL ANTI-INFLAMMATORY is contraindicated in children under 14 years of age. \u003cb\u003eElderly:\u003c\/b\u003e The usual dosage for adults can be used. \u003cb\u003eHow to use: \u003c\/b\u003e Shake before use. Holding the can upside down, dispense the desired quantity by pressing the appropriate dispenser.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at a temperature not exceeding 30°C. This medicine contains flammable propellant. Protect from sunlight and do not expose to temperatures above 50°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see the summary of product characteristics of systemic forms of diclofenac). Topical Diclofenac should only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. In elderly patients and\/or with gastric problems, the concomitant use of systemic anti-inflammatory drugs is not recommended. LOCAL ANTI-INFLAMMATORY DICLOREUM should be used with caution in patients who have had a hypersensitivity reaction to NSAIDs or analgesics in the past, e.g. asthma attacks, skin rashes or acute allergic rhinitis. Asthmatic patients, with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to antirheumatic treatment carried out with NSAIDs more often than other patients. The use, especially if prolonged, of other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Discontinue treatment if skin rash develops after application of the product. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. DICLOREUM LOCAL ANTI-INFLAMMATORY contains potassium sorbate which can cause local skin reactions (e.g. contact dermatitis). This medicine contains 7.5 mg of benzyl alcohol per dose. Benzyl alcohol can cause allergic reactions. Benzyl alcohol may cause mild local irritation. This medicine contains a mint\/eucalyptus fragrance which in turn contains geraniol, limonene and linalool which may cause allergic reactions. To reduce any photosensitization phenomena, it is advisable not to expose yourself excessively to the sun during use. \u003cb\u003eKeep the medicine out of the sight and reach of children.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, such interactions are very unlikely. However, in high-dose and prolonged treatments, keep in mind the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); Not known: cannot be estimated from available data.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eThe use of the medicine in combination with other drugs containing diclofenac can give rise to phenomena of hypersensitivity to light, skin rash with the formation of vesicles, eczema, erythema and severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome). Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of topical diclofenac makes overdose very unlikely. However, side effects similar to those seen after an overdose of diclofenac tablets can be expected if topical diclofenac is inadvertently ingested (a 50 g canister contains 1.5 g of Diclofenac). In the event of accidental ingestion resulting in significant systemic side effects, the general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Gastric decontamination and the use of activated charcoal should be taken into consideration, especially within a short time of ingestion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e The systemic concentration of diclofenac, compared to oral formulations, is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may have negative effects on pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of DICLOREUM LOCAL ANTI-INFLAMMATORY no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, DICLOREUM ANTI-INFLAMMATORY LOCAL must not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCutaneous application of topical diclofenac does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51131339505991,"sku":"042685040","price":16.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-dicloreum-antinfiammatorio-locale-3-schiuma-cutanea-50g-farmacia-dottor-tili-1213792022.jpg?v=1767148869"},{"product_id":"voltadol-140mg-5-cerotti-medicati","title":"Voltadol 140mg 5 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA medicated plaster contains: active ingredient: diclofenac sodium 140 mg. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eButyl-methacrylate-copolymer-basic; acrylate-vinyl-acetate copolymer; polyethylene glycol 12 stearate; sorbitan oleate; non-woven fabric; silicone paper.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance, to acetylsalicylic acid or to other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients listed in paragraph 6.1. Patients with a history of asthma, angioedema, urticaria or acute rhinitis after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. Third trimester of pregnancy (see section 4.6). Patients with active peptic ulcer. Children and adolescents under the age of 16.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. \u003cb\u003eDosage\u003c\/b\u003e VOLTADOL should only be applied to intact, healthy skin and should not be applied when bathing or showering. VOLTADOL should be used for the shortest possible time. \u003cu\u003eAdults and adolescents aged 16 and over:\u003c\/u\u003e Apply a patch 2 times a day, in the morning and in the evening, on the skin of the area to be treated, for a period of no more than 7 days. Do not exceed the recommended dose. If there is no improvement or worsening of symptoms is reported after 7 days of treatment, reassess the situation (see section 4.4). \u003cu\u003eSpecial populations\u003c\/u\u003e \u003ci\u003e \u003cu\u003eChildren and adolescents under 16 years of age:\u003c\/u\u003e \u003c\/i\u003e VOLTADOL is contraindicated in children and adolescents under 16 years of age (see section 4.3). \u003ci\u003e \u003cu\u003eElderly and patients with hepatic or renal insufficiency\u003c\/u\u003e \u003c\/i\u003e VOLTADOL should be used with caution (see section 4.4). \u003cb\u003eMethod of administration\u003c\/b\u003e 1 - Cut the envelope along the dotted line and remove the patch. \u003cu\u003eFor applying the plaster\u003c\/u\u003e: 2 - Remove one of the two protective sheets. 3 - Apply to the part to be treated and remove the remaining protective sheet. 4 - Exert light pressure with the palm of your hand until it adheres completely to the skin. The patch must be used whole. \u003cu\u003eFor removing the plaster\u003c\/u\u003e: 5 - Wet the patch with water and then lift one edge by pulling gently. 6 - To eliminate any residues of the product, wash the affected area with water using circular movements with your fingers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf VOLTADOL is used for a prolonged period of time, the possibility of systemic adverse events cannot be excluded. VOLTADOL should only be applied to intact, healthy skin, and should not be applied to damaged skin or open wounds. The patches must not come into contact with the eyes or mucous membranes and must not be swallowed. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Treatment should be stopped immediately if a skin rash develops after application of the medicated plaster. Patients with asthma, chronic obstructive bronchial diseases, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to treatment with NSAIDs more often than other patients. The administration of VOLTADOL must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and establish a suitable therapy. Although systemic absorption is minimal, the use of VOLTADOL is not recommended in women planning to become pregnant. Do not simultaneously administer topically or systemically another medicinal product containing diclofenac or other NSAIDs. The use of VOLTADOL in combination with other drugs containing diclofenac can give rise to severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome). Given the route of administration, the risk of systemic effects is lower, however the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or haemorrhagic diathesis. NSAIDs should be used with particular caution in elderly patients who are more predisposed to side effects. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. Patients should be advised not to expose themselves to direct sunlight or light from sunlamps for approximately one day after removal of the medicated plaster in order to reduce the risk of photosensitivity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac following the use of medicated plasters is low. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003eReporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCases of overdose with VOLTADOL have been reported, but no systemic adverse effects that may be caused by overdose with oral NSAIDs (e.g. vomiting, diarrhea, dizziness, tinnitus, gastrointestinal bleeding, convulsions) have been reported. However, side effects similar to those observed after an overdose of diclofenac tablets can be expected if topical diclofenac is inadvertently ingested (1 pack of 10 patches contains 1400 mg of diclofenac sodium). Should systemic side effects occur due to incorrect use or accidental overdose (e.g. in children), general supportive therapeutic measures are recommended with the product to be undertaken in case of intoxication with non-steroidal anti-inflammatory drugs. Further treatment modalities should take into account the recommendations of the poison control center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePregnancy\u003c\/i\u003e The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios. The mother and the newborn, at the end of pregnancy, are exposed to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003ci\u003eBreastfeeding\u003c\/i\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of VOLTADOL no effects on the infant are expected. Due to the lack of controlled studies in women breastfeeding, the administration of VOLTADOL during breastfeeding should only be considered if the expected benefit for the mother outweighs the risk for the child. In this circumstance, Voltadol must not be applied to the breasts of breastfeeding mothers, nor for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVOLTADOL does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51131353891143,"sku":"035520016","price":15.76,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltadol-140mg-5-cerotti-medicati-farmacia-dottor-tili-1213791958.jpg?v=1767141090"},{"product_id":"dolaut-40-mg-g-25-g-gel-con-erogatore","title":"Dolaut 40 mg\/g 25 g gel with dispenser","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach 100 g of gel contains: Active ingredient: Diclofenac sodium 4 g Excipient with known effects: propylene glycol For the complete list of excipients, see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePropylene glycol, Isopropyl alcohol, Ethyl alcohol, Soy lecithin, Sodium phosphate dihydrate, Disodium phosphate dodecahydrate, Disodium edetate, Ascorbyl palmitate, Mint essence, Purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Children and adolescents: use in children and adolescents under 14 years of age is contraindicated. Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAdults over 18 years:\u003c\/b\u003e Apply DOLAUT 3 or 4 times a day on the area to be treated, rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 3-5 sprays of DOLAUT are sufficient to treat an area of ​​400-800 cm². After application, wash your hands, otherwise they will also be treated with the gel. Attention: use only for short treatment periods. \u003cb\u003eAdolescents aged 14 to 18:\u003c\/b\u003e Apply DOLAUT 3 or 4 times a day on the area to be treated, rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 3-5 sprays of DOLAUT are sufficient to treat an area of ​​400-800 cm². After application, wash your hands, otherwise they will also be treated with the gel. If this product is needed for more than 7 days to relieve pain or if symptoms worsen, consult your doctor. \u003cb\u003eChildren under 14 years:\u003c\/b\u003e Insufficient data are available on efficacy and safety in children and adolescents under 14 years (see also section 4.3 Contraindications). Therefore the use of DOLAUT is contraindicated in children under 14 years of age. \u003cb\u003eElderly:\u003c\/b\u003e The usual dosage for adults can be used.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKeep away from heat sources and open flames\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see the summary of product characteristics of systemic forms of diclofenac). Therefore, particularly in patients with previous gastrointestinal diseases, the appearance of systemic side effects such as nausea, dyspepsia, heartburn, excitation, taste alteration, conjunctivitis cannot be excluded for DOLAUT. Topical Diclofenac should only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. DOLAUT contains propylene glycol which may cause mild localized skin irritation in some people. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. External use. KEEP OUT OF THE REACH OF CHILDREN.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, such interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, the most frequent first, using the following convention: very common (≥ 1\/10); common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); Not known: frequency cannot be estimated from the available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rush with pustules.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eNot known: Burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of topical diclofenac makes overdose very unlikely. However, side effects similar to those seen after an overdose of diclofenac tablets can be expected if topical diclofenac is inadvertently ingested (1 25 g bottle contains the equivalent of 1000 mg of diclofenac sodium). In the event of accidental ingestion resulting in significant systemic side effects, the general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Gastric decontamination and the use of activated charcoal should be taken into consideration, especially within a short time of ingestion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac, compared to oral formulations, is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended. Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding \u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of DOLAUT no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, DOLAUT should not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCutaneous application of topical diclofenac does not alter the ability to drive or use machinery\u003c\/p\u003e","brand":"Neopharmed Gentili","offers":[{"title":"Default Title","offer_id":51730203115847,"sku":"033913017","price":16.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/neopharmed-gentili-spa-dolaut-40-mg-g-25-g-gel-con-erogatore-farmacia-dottor-tili-1213791433.jpg?v=1767138450"},{"product_id":"cerotto-bertelli-96-5-mg-368-6-mg-1-cerotto-16-24-cm-medicato","title":"Bertelli patch 96.5 mg (368.6 mg) 1 medicated patch 16×24 cm","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of muscle pain such as low back pain.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne medicated plaster contains: active ingredient: 96.5 mg of refined and titrated Capsicum oleoresin, from dried ripe fruits of \u003ci\u003eCapsicum annuum\u003c\/i\u003e L. var. \u003ci\u003eminimum\u003c\/i\u003e Miller (Heiser) or \u003ci\u003eCapsicum frutescens\u003c\/i\u003e L. small fruit variety, corresponding to 12.2 mg (32 mcg\/cm²) of capsaicinoids expressed as capsaicin. Extraction solvent: ethanol minimum 90% V\/V. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eArnica essence, olibanum, natural rubber, iron oxide, staybelite resin, staybelite ester 3, Hercolin, iris rhizome, methyl p-hydroxy-benzoate, 2,2' methylene-bis-(4 methyl-6 tertbutylphenol), castor oil (excipient of the herbal preparation).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active ingredient or to other sources of capsaicinoids (for example pepper or chilli plants. Broken skin, wounds and eczema.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDosage Adults The recommended dose is 1 medicated plaster per day to be applied to the affected area and left on for at least 4-12 hours. An interval of at least 12 hours must elapse before applying a new patch to the same application area. Do not exceed the maximum recommended daily dose. Pediatric population The safety and efficacy of Cerotto Bertelli in children and adolescents has not been established. No data available. Method of administration Cutaneous use. Apply to dry skin and adhere with a light massage. Duration of treatment Use for a short period. Prolonged use should be established after adequate clinical evaluation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt is advisable to remove Cerotto Bertelli using a cotton ball soaked in warm water or olive oil. The medicine should not be applied near the eyes or on the mucous membranes. During treatment, the application of additional heat sources (e.g. solar or infrared radiation, heat cushion or hot water) should be avoided. The effect of heat can also be intensified by physical activity (sweating). Treatment must be stopped if the heat effect occurs excessively. In this case the patch must be removed. If symptoms worsen while using the medicine, consult your doctor or pharmacist.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known interactions of any kind with other medicinal products. No interaction studies have been performed. The patch is not intended to be applied at the same time as other topical products [e.g. other rubefacients (which increase perfusion and cause redness of the skin) or pain-relieving gels] at the same application site. Interactions with other products applied to the same application site may occur up to 12 hours after removal of the patch.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of the product for topical use, especially if prolonged, may give rise to sensitization phenomena. The active ingredient causes an increase in local blood circulation with marked redness of the skin and a sensation of heat. This reaction is part of the normal pharmacological action of the preparation and generally subsides shortly after removal of the patch. In rare cases (≈1\/10,000, \u003c1\/1,000): Skin hypersensitivity and allergic reactions (e.g. urticaria, vesicles and vesiculation at the application site) may occur. In these cases treatment must be stopped immediately. Especially during the first days of treatment, a sensation of irritation or itching may occur. If, in individual cases, the side effects experienced are excessive, treatment must be discontinued. \u003cb\u003e \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the Website: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA relative overdose may be due to inadequate use of the preparation which can cause local irritation phenomena which require suspension of the drug and generic anti-inflammatory treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo contraindications for use during pregnancy and breastfeeding are described. Pregnancy There are no data on use in pregnant women. Breastfeeding Animal studies have shown reproductive toxicity after high subcutaneous doses of capsaicin. Capsaicin crosses the placenta and can pass into breast milk. Although prenatal and neonatal effects have occurred at doses exceeding the maximum clinical dose of the patch, the patch should be used during pregnancy and breastfeeding only after careful evaluation of the risk-benefit ratio. Fertility No data on fertility are available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNobody.\u003c\/p\u003e","brand":"Kelemata","offers":[{"title":"Default Title","offer_id":51730205901127,"sku":"004844027","price":9.41,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/kelemata-srl-cerotto-bertelli-96-5-mg-368-6-mg-1-cerotto-16x24-cm-medicato-farmacia-dottor-tili-1213791367.jpg?v=1767139768"},{"product_id":"voltadol-unidie-140-mg-5-cerotti-medicati","title":"Voltadol Unidie 140 mg 5 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term local treatment (maximum 7 days) of pain associated with muscle strains, sprains or bruises of arms and legs due to blunt trauma in adolescents from 16 years of age and in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach medicated plaster contains 140 mg of sodium diclofenac. Each medicated plaster contains 2.90 mg of butylated hydroxyanisole (E 320). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSupport layer:\u003c\/u\u003e Non-woven polyester. \u003cu\u003eAdhesive layer:\u003c\/u\u003e polyacrylate dispersion, tributyl citrate, butylated hydroxyanisole (E 320). \u003cu\u003eProtective layer:\u003c\/u\u003e monosiliconed paper.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Hypersensitivity to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs [NSAIDs] - Patients who have had attacks of asthma, urticaria or acute rhinitis in the past after the use of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Patients with active peptic ulcer. - Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. - Third trimester of pregnancy. - Children and adolescents under 16 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003e \u003cu\u003eAdults and adolescents aged 16 and over\u003c\/u\u003e \u003c\/i\u003e Apply a medicated plaster once a day to the painful area. The maximum daily dose is 1 medicated plaster, even if there are more than one areas to be treated. Therefore, only one painful area can be treated at a time. \u003ci\u003e \u003cu\u003eDuration of use\u003c\/u\u003e \u003c\/i\u003e Voltadol Unidie should be used for the minimum time necessary to control symptoms. The use of the patch must not exceed 7 days. A therapeutic benefit for longer duration administrations has not yet been demonstrated. \u003ci\u003e \u003cu\u003eElderly patients\u003c\/u\u003e \u003c\/i\u003e The medicine should be used with caution in elderly patients as they are more predisposed to side effects (see also section 4.4). \u003ci\u003e \u003cu\u003ePatients with renal or hepatic impairment\u003c\/u\u003e \u003c\/i\u003e For the treatment of patients with renal or hepatic impairment see section 4.4. \u003ci\u003e \u003cu\u003ePediatric population\u003c\/u\u003e \u003c\/i\u003e There are insufficient data on the efficacy and safety of Voltadol Unidie in children and adolescents under 16 years of age (see section 4.3). The patient\/parents of the adolescent are advised to consult a doctor if it is necessary to administer the medicine for more than 7 days to relieve pain or if symptoms worsen. \u003cu\u003eMethod of administration\u003c\/u\u003e Cutaneous use. The medicated plaster must only be applied to intact, healthy skin and must not be applied when bathing or showering. The medicated plaster must not be divided. If necessary, the medicated plaster can be kept in place using an elastic mesh bandage. The medicated plaster must not be used with an occlusive dressing.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in the original package to protect the medicine from light and moisture.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicated plaster must not come into contact with or be applied to the eyes or mucous membranes. Undesirable effects can be reduced by using the lowest effective dose for the shortest possible time (see section 4.2). Bronchospasm may occur in patients who suffer or have suffered in the past from bronchial asthma or allergies. If a rash develops after applying the medicated plaster, treatment should be stopped immediately. After removal of the medicated plaster, patients should be informed of the need to avoid exposure to sunlight or sunlamps, in order to reduce the risk of photosensitization. It is not possible to exclude the possibility of systemic adverse events resulting from the application of diclofenac medicated plaster, if the product is used on large skin surfaces for a prolonged period of time. Although systemic effects may be minimal, the medicated plaster should be used with caution in patients with impaired renal, cardiac or hepatic function, or with a history of peptic ulcer, intestinal inflammation or haemorrhagic diathesis. Non-steroidal anti-inflammatory drugs should be used with caution in elderly patients, as these subjects are more exposed to the onset of side effects. Do not simultaneously administer, topically or systemically, any other medicinal product containing diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs). Butylated hydroxyanisole (E 320) may cause localized skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac with the methods of use of medicated plasters indicated on the label is very low, the risk of developing clinically significant interactions between drugs is negligible.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects are reported based on the following frequency categories:\u003c\/p\u003e\n\u003cp\u003eVery common: ≥1\/10.\u003c\/p\u003e\n\u003cp\u003eCommon: ≥ 1\/100 to \u003c1\/10.\u003c\/p\u003e\n\u003cp\u003eUncommon: ≥1\/1,000 to \u003c1\/100.\u003c\/p\u003e\n\u003cp\u003eRare: ≥1\/10,000 to \u003c1\/1,000.\u003c\/p\u003e\n\u003cp\u003eVery rare: \u003c1\/10,000.\u003c\/p\u003e\n\u003cp\u003eNot known: Frequency cannot be estimated from the available data.\u003c\/p\u003e\n\u003cp\u003eInfections and manifestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Pustular rash.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003eThe levels of diclofenac measured in systemic plasma according to the methods of use of the medicated plasters indicated on the label are very low when compared with those detected after oral intake of diclofenac. The risk of developing systemic side effects (such as gastric, hepatic and renal disorders, systemic hypersensitivity reactions), therefore, appears low with the use of the patch. However, if diclofenac is used on large skin surfaces and for long periods of time, the appearance of systemic side effects is possible. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported with diclofenac medicated plasters. If serious systemic side effects occur following incorrect use of the drug or accidental overdose (e.g. in children), the appropriate precautionary measures used for intoxication with non-steroidal anti-inflammatory drugs should be applied.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e The systemic concentration of diclofenac following topical administration is lower than that related to oral formulations. Referring to the experience deriving from treatment with systemic NSAIDs, the following is recommended: inhibition of prostaglandin synthesis may lead to negative effects during pregnancy and\/or during embryonic\/fetal development. Data deriving from epidemiological studies suggest an increased risk of spontaneous abortion, cardiac malformations and gastroschisis, following the use of prostaglandin synthesis inhibitors in the first months of pregnancy. The absolute risk of cardiovascular malformations was increased from a value of less than 1% up to a maximum of approximately 1.5%. The risk is thought to increase with increasing dose and duration of treatment. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramniosis; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time and anti-aggregating effect, which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e Diclofenac, in small quantities, is secreted into breast milk. However, at therapeutic doses of diclofenac medicated plaster, there are no effects on the infant. Given the lack of controlled clinical studies in breastfeeding women, the medicine should be used during breastfeeding only on the advice of a healthcare professional. In this case, Voltadol Unidie should not be applied to the breasts of breastfeeding mothers, nor elsewhere on large skin surfaces or for a prolonged period of time.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVoltadol Unidie does not alter the ability to drive and use machines.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51730205999431,"sku":"048717021","price":18.09,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltadol-unidie-140-mg-5-cerotti-medicati-farmacia-dottor-tili-1213791364.jpg?v=1767139832"},{"product_id":"voltalgan-3-50-g-schiuma-cutanea","title":"Voltalgan 3% 50 g skin foam","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e100 g of skin foam contains:\u003c\/i\u003e Diclofenac 3 g For the complete list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSodium hydroxide, caprylocapric macrogolglycerides, hydrogenated soy lecithin, polysorbate 80, benzyl alcohol, potassium sorbate, disodium phosphate dodecahydrate, all-rac-α-tocopheryl acetate, mint\/eucalyptus fragrance, purified water. \u003ci\u003eEach pressurized container (50 g) contains\u003c\/i\u003e: 47.5 g of solution and 2.5 g of propellant (isobutane; n-butane; propane).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Patients verified with a history of asthma, angioedema, urticaria or acute rhinitis after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds (see section 4.4). Third trimester of pregnancy (see section 4.6). Children and adolescents under the age of 14.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAdults and adolescents aged 14 and over\u003c\/b\u003e: Apply VOLTALGAN skin foam 1-3 times a day. For each application, spray a circular mass of foam 3-5 centimeters in diameter (equal to approximately 0.75-1.5 grams in weight) onto the palm of your hand, depending on the size of the area to be treated, massaging delicately until completely absorbed. In case of iontophoresis treatment, the product must be applied to the negative pole. VOLTALGAN skin foam can also be used in combination with ultrasound therapy. After application, ask the patient to wash their hands, otherwise they will also be treated with skin foam. Warning: the product must only be used for short treatment periods. If the product is needed for more than 7 days to relieve pain or if symptoms worsen, the doctor should reassess the situation (see section 4.4). \u003cb\u003eChildren under 14 years:\u003c\/b\u003e Insufficient data are available on efficacy and safety in children and adolescents under 14 years of age (see also section 4.3 Contraindications). Therefore the use of Voltalgan skin foam is contraindicated in children under 14 years of age. \u003cb\u003eElderly\u003c\/b\u003e: The usual dosage for adults can be used. \u003ci\u003e \u003cu\u003eHow to use:\u003c\/u\u003e \u003c\/i\u003e Shake before use. With the canister upside down, dispense the desired quantity by pressing the appropriate dispenser. For cutaneous use only.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 30°C. \u003ci\u003ePressurized container\u003c\/i\u003e: VOLTALGAN contains flammable propellant. Protect against sunlight and do not expose to temperatures above 50°C. Store away from any source of ignition.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of VOLTALGAN cannot be excluded if the preparation is used on large skin areas and for a prolonged period. VOLTALGAN must be applied only to intact, unaffected skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. It is necessary to discontinue treatment if skin rash develops after application of the product. VOLTALGAN can be used with non-occlusive bandages, but must not be used with an occlusive dressing that does not allow air to pass through. In elderly patients and\/or with gastric problems, the concomitant use of systemic anti-inflammatory drugs is not recommended. Asthmatic patients, with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp), react, with asthmatic attacks, local inflammation of the skin, mucosa (Quincke's edema) or urticaria, to antirheumatic treatment carried out with NSAIDs, more often than other patients. The administration of VOLTALGAN must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use of VOLTALGAN, especially if prolonged, can give rise to local sensitization phenomena, which require the interruption of treatment and the adoption of adequate therapeutic measures. To reduce any photosensitivity phenomena, patients should be advised not to expose themselves to direct sunlight or light from sunlamps during use. In case of allergic reactions or more serious adverse reactions, it is necessary to suspend treatment with VOLTALGAN and establish adequate therapy. The use of the medicine in combination with other medicines containing diclofenac can give rise to severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome). VOLTALGAN contains 7.5 mg of benzyl alcohol per dose (equivalent to 1.5 grams by weight). Benzyl alcohol may cause allergic reactions and mild local irritation. VOLTALGAN contains an aroma which in turn contains limonene. Limonene can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac following topical application is very low. In high-dose and prolonged treatments, keep in mind the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, the most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10), uncommon (≥ 1\/1000, \u003c 1\/100), rare (≥ 1\/10,000, \u003c 1\/1,000), very rare (\u003c1\/10,000); not known: cannot be estimated from available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eNot known: Dry skin, burning sensation on application.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions \u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCases of overdose with VOLTALGAN have been reported, but no systemic adverse effects that may be caused by overdose with oral NSAIDs (e.g. vomiting, diarrhea, dizziness, tinnitus, gastrointestinal bleeding, convulsions) have been reported. However, side effects similar to those seen after an overdose of diclofenac tablets can be expected if topical diclofenac is inadvertently ingested (1 50 g pressurized foam container contains approximately 1.54 g of diclofenac sodium). In case of accidental ingestion, which gives rise to significant systemic side effects, the general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Further treatment modalities should take into account the recommendations of the poison control center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: • cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); • renal dysfunction, which can progress to renal failure with oligohydroamnios; the mother and the newborn, at the end of pregnancy, to: • possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; • inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of VOLTALGAN no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only if the expected benefit to the mother outweighs the risk to the baby. In this circumstance, VOLTALGAN must not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4). \u003cb\u003eFertility \u003c\/b\u003e No data are available on the effects of diclofenac for topical use on fertility.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVOLTALGAN has no or negligible influence on the ability to drive or use machinery.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51730206163271,"sku":"037645013","price":15.77,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltalgan-3-50-g-schiuma-cutanea-farmacia-dottor-tili-1213791360.jpg?v=1767139870"},{"product_id":"voltadol-140-mg-10-cerotti-medicati","title":"Voltadol 140 mg 10 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA medicated plaster contains: active ingredient: diclofenac sodium 140 mg. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eButyl-methacrylate-copolymer-basic; acrylate-vinyl-acetate copolymer; polyethylene glycol 12 stearate; sorbitan oleate; non-woven fabric; silicone paper.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance, to acetylsalicylic acid or to other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients listed in paragraph 6.1. Patients with a history of asthma, angioedema, urticaria or acute rhinitis after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. Third trimester of pregnancy (see section 4.6). Patients with active peptic ulcer. Children and adolescents under the age of 16.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. \u003cb\u003eDosage\u003c\/b\u003e VOLTADOL should only be applied to intact, healthy skin and should not be applied when bathing or showering. VOLTADOL should be used for the shortest possible time. \u003cu\u003eAdults and adolescents aged 16 and over:\u003c\/u\u003e Apply a patch 2 times a day, in the morning and in the evening, on the skin of the area to be treated, for a period of no more than 7 days. Do not exceed the recommended dose. If there is no improvement or worsening of symptoms is reported after 7 days of treatment, reassess the situation (see section 4.4). \u003cu\u003eSpecial populations\u003c\/u\u003e \u003ci\u003e \u003cu\u003eChildren and adolescents under 16 years of age:\u003c\/u\u003e \u003c\/i\u003e VOLTADOL is contraindicated in children and adolescents under 16 years of age (see section 4.3). \u003ci\u003e \u003cu\u003eElderly and patients with hepatic or renal insufficiency\u003c\/u\u003e \u003c\/i\u003e VOLTADOL should be used with caution (see section 4.4). \u003cb\u003eMethod of administration\u003c\/b\u003e 1 - Cut the envelope along the dotted line and remove the patch. \u003cu\u003eFor applying the plaster\u003c\/u\u003e: 2 - Remove one of the two protective sheets. 3 - Apply to the part to be treated and remove the remaining protective sheet. 4 - Exert light pressure with the palm of your hand until it adheres completely to the skin. The patch must be used whole. \u003cu\u003eFor removing the plaster\u003c\/u\u003e: 5 - Wet the patch with water and then lift one edge by pulling gently. 6 - To eliminate any residues of the product, wash the affected area with water using circular movements with your fingers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf VOLTADOL is used for a prolonged period of time, the possibility of systemic adverse events cannot be excluded. VOLTADOL should only be applied to intact, healthy skin, and should not be applied to damaged skin or open wounds. The patches must not come into contact with the eyes or mucous membranes and must not be swallowed. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Treatment should be stopped immediately if a skin rash develops after application of the medicated plaster. Patients with asthma, chronic obstructive bronchial diseases, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to treatment with NSAIDs more often than other patients. The administration of VOLTADOL must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and establish a suitable therapy. Although systemic absorption is minimal, the use of VOLTADOL is not recommended in women planning to become pregnant. Do not simultaneously administer topically or systemically another medicinal product containing diclofenac or other NSAIDs. The use of VOLTADOL in combination with other drugs containing diclofenac can give rise to severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome). Given the route of administration, the risk of systemic effects is lower, however the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or haemorrhagic diathesis. NSAIDs should be used with particular caution in elderly patients who are more predisposed to side effects. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. Patients should be advised not to expose themselves to direct sunlight or light from sunlamps for approximately one day after removal of the medicated plaster in order to reduce the risk of photosensitivity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac following the use of medicated plasters is low. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003eReporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCases of overdose with VOLTADOL have been reported, but no systemic adverse effects that may be caused by overdose with oral NSAIDs (e.g. vomiting, diarrhea, dizziness, tinnitus, gastrointestinal bleeding, convulsions) have been reported. However, side effects similar to those observed after an overdose of diclofenac tablets can be expected if topical diclofenac is inadvertently ingested (1 pack of 10 patches contains 1400 mg of diclofenac sodium). Should systemic side effects occur due to incorrect use or accidental overdose (e.g. in children), general supportive therapeutic measures are recommended with the product to be undertaken in case of intoxication with non-steroidal anti-inflammatory drugs. Further treatment modalities should take into account the recommendations of the poison control center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePregnancy\u003c\/i\u003e The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios. The mother and the newborn, at the end of pregnancy, are exposed to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003ci\u003eBreastfeeding\u003c\/i\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of VOLTADOL no effects on the infant are expected. Due to the lack of controlled studies in women breastfeeding, the administration of VOLTADOL during breastfeeding should only be considered if the expected benefit for the mother outweighs the risk for the child. In this circumstance, Voltadol must not be applied to the breasts of breastfeeding mothers, nor for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVOLTADOL does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51730206589255,"sku":"035520028","price":23.81,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltadol-140-mg-10-cerotti-medicati-farmacia-dottor-tili-1213791022.jpg?v=1767140125"},{"product_id":"miotens-0-25-30-ml-schiuma-cutanea","title":"Miotens 0.25% 30 ml skin foam","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLumbosciatica (back pain), cervico-brachial neuralgia (pain and contracture affecting the neck, shoulder and upper limbs), stubborn stiff necks, post-traumatic and post-operative pain syndromes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml, as a solution, contain: \u003ci\u003eActive ingredient\u003c\/i\u003e: thiocolchicoside 0.25 g Excipients: propylene glycol For the complete list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePolysorbate 80, propylene glycol, ethyl alcohol, propylene glycol dipelargonate, benzyl alcohol, monobasic sodium phosphate monohydrate, dibasic sodium phosphate dodecahydrate, Nerolene lavender, purified water. Propellant: propane-butane mixture (propane\/n-butane\/iso-butane).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. Flaccid paralysis, muscular hypotonicity. Pregnancy and breastfeeding (see 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply an amount of foam based on the size of the area that needs to be treated 2-3 times a day. The treatment can be associated with physical-rehabilitative therapies. \u003ci\u003e \u003cu\u003eMethod of administration\u003c\/u\u003e:\u003c\/i\u003e shake before use and press the dispenser while holding the container upside down.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMIOTENS CONTRACTURES AND PAIN 0.25% skin foam: keep away from heat. Contains flammable propellant. Do not expose to temperatures above 50°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe dosage should be appropriately reduced in the event of the appearance of side effects. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. If they occur, treatment must be discontinued and appropriate therapy instituted. MIOTENS CONTRACTURES AND PAIN contains propylene glycol: may cause skin irritation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo notes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCases of rash and skin erythema have been reported. See also paragraph 4.4.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose are known or have been reported in the literature.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough a teratogenic effect was not observed in animal studies except when thiocolchicoside was administered at doses much higher than those recommended in human therapy (more than 10 times the therapeutic dose), as a precaution, the use of the product is contraindicated during pregnancy. Since the drug passes into breast milk, its use during breastfeeding is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough after the administration of MIOTENS CONTRACTURES AND PAIN the appearance of drowsiness is to be considered a very rare occurrence, it is still necessary to take this possibility into account.\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":51730207015239,"sku":"042045017","price":12.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/dompe-farmaceutici-spa-miotens-0-25-30-ml-schiuma-cutanea-farmacia-dottor-tili-1213791065.jpg?v=1767140110"},{"product_id":"voltaren-emulgel-1-120-g-gel","title":"Voltaren Emulgel 1% 120 g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons and ligaments (such as tendonitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e contain 1.16 g of diclofenac diethylammonium, equivalent to 1 g of diclofenac sodium. Excipients with known effects: propylene glycol (50 mg\/g gel); benzyl benzoate (1 mg\/g gel); Cream 45 perfume. For the complete list of excipients, see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDiethylamine, carbomers, macrogol cetostearyl ether, cocoyl caprylocaprate, isopropyl alcohol, liquid paraffin, \u003cb\u003eCream 45 perfume\u003c\/b\u003e (contains \u003cb\u003ebenzyl benzoate\u003c\/b\u003e), \u003cb\u003epropylene glycol\u003c\/b\u003e, purified water\u003cb\u003e.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Patients in whom asthma, angioedema, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Third trimester of pregnancy. \u003cu\u003eChildren and adolescents\u003c\/u\u003e: Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAdults over 18 years:\u003c\/b\u003e Apply \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e 3 or 4 times a day on the area to be treated, rubbing lightly. The quantity to be applied depends on the size of the affected part. For example 2-4 g of \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of 400-800 cm². After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 1% to dry before showering or bathing. Warning: use only for short treatment periods. \u003cb\u003eAdolescents aged 14 to 18\u003c\/b\u003e Apply Voltaren Emulgel \u003ci\u003e1% gel\u003c\/i\u003e 3 or 4 times a day on the area to be treated, rubbing lightly. The quantity to be applied depends on the size of the affected part. For example 2-4 g of Voltaren Emulgel \u003ci\u003e1% gel\u003c\/i\u003e (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of 400-800 cm². After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 1% to dry before showering or bathing. If this product is needed for more than 7 days for pain relief or if symptoms worsen, consult a doctor. \u003cb\u003eChildren under 14 years:\u003c\/b\u003e Insufficient data are available on efficacy and safety in children and adolescents under 14 years (see also section 4.3 Contraindications). Therefore, the use of Voltaren Emulgel \u003ci\u003e1% gel\u003c\/i\u003e It is contraindicated in children under six 14 years of age. \u003cb\u003eElderly (over 65 years):\u003c\/b\u003e The usual dosage for adults can be used.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eTube of 60 g, 100 g, 120 g, 150 g gel and 120 g 1% gel with applicator cap\u003c\/u\u003e: Store below 30°C. \u003cu\u003e50 g pressurized container\u003c\/u\u003e: Store below 30°C. Warning: the container is under pressure: store away from direct sunlight, do not puncture or burn the container, even after use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see the summary of product characteristics of systemic forms of diclofenac\u003ci\u003e).\u003c\/i\u003e Topical diclofenac should only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e contains 200 mg of propylene glycol per dose (4 g) equivalent to 50 mg\/g and 4 mg of benzyl benzoate per dose (4 g) equivalent to 1 mg\/g which may cause skin irritation. \u003cb\u003e \u003ci\u003eVoltaren Emulgel 1% gel contains Cream 45 perfume, an aroma which in turn contains benzyl alcohol, citral, citronellol, coumarin, d-limonene, eugenol, farinasol, geraniol, linalool which may cause allergic reactions.\u003c\/i\u003e \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, such interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: very common (≥1\/10), common (≥1\/100, \u003c1\/10); uncommon (≥ 1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction, allergic reactions.\u003c\/p\u003e\n\u003cp\u003eNot known: Burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of topical diclofenac makes overdose very unlikely. However side effects similar to those observed after an overdose of diclofenac tablets\u003ci\u003e,\u003c\/i\u003e can be expected if topical diclofenac is ingested (1 60 g tube contains the equivalent of 600 mg of sodium diclofenac). In case of ingestion resulting in significant systemic side effects, the general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Further treatment modalities, within the short term of ingestion, should take into account clinical indications or the recommendation of the poison control center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e it must not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCutaneous application of topical diclofenac does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":51730207375687,"sku":"034548204","price":15.35,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/novartis-farma-spa-voltaren-emulgel-1-120-g-gel-farmacia-dottor-tili-1213791095.jpg?v=1767140310"},{"product_id":"dicloreum-unidie-136-mg-5-cerotti-medicati","title":"Dicloreum Unidie 136 mg 5 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDICLOREUM UNIDIE is indicated for the local treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne medicated plaster contains: active ingredient: ibuprofen 136 mg. For the complete list of excipients see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePotassium salt of the copolymer of 2-ethylhexyl acrylate, methyl acrylate, acrylic acid, glycidyl methacrylate; oleic acid; Al\u003csup\u003e+3\u003c\/sup\u003e. \u003ci\u003eSupport Matrix:\u003c\/i\u003e PET. \u003ci\u003eProtective film:\u003c\/i\u003e Siliconized PET.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance (ibuprofen) or to any of the excipients. The use of DICLOREUM UNIDIE is contraindicated in subjects in whom a previous hypersensitivity to acetylsalicylic acid or other analgesics or non-steroidal anti-inflammatory drugs has occurred, in patients with previous episodes of bronchospasm, angioedema or anaphylactoid reactions. The administration of DICLOREUM UNIDIE should be avoided in patients suffering from active peptic ulcers, bronchial asthma or suffering from severe renal and hepatic insufficiency. The use of DICLOREUM UNIDIE should also be avoided in patients with a history of gastrointestinal haemorrhage or perforation relating to previous active treatments or a history of recurrent haemorrhage\/peptic ulcer (two or more distinct episodes of demonstrated ulceration or bleeding), on therapy with anticoagulants (see section 4.5) and finally in cases of severe heart failure. Also avoid applying the medicated plaster on damaged skin or in areas with dermatoses or infections. Avoid contact with eyes and mucous membranes. The use of DICLOREUM UNIDIE is contraindicated during the third trimester of pregnancy and breastfeeding (see section 4.6) and in children under 12 years.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse only one medicated plaster at a time and replace it every 24 hours for a maximum duration of 7-10 days. DICLOREUM UNIDIE is to be used exclusively for applications on intact skin. It is advisable to wash and dry the painful area carefully before applying the medicated plaster. If the medicated plaster must be positioned on joints subject to wide mobility, such as the elbow or knee, we recommend applying it longitudinally and not transversely, taking care to attach the medicated plaster while keeping the joint partially flexed. To apply the medicated plaster, partially detach the two parts of transparent protective film in the central area of ​​the medicated plaster so as to have a free adhesive surface of 2 - 3 centimeters and adhere this part to the skin of the central area of ​​the painful point. Slowly peel off the two protective films one after the other, taking care to prevent the medicated plaster from creasing or sticking to itself. Immediately after attaching the medicated plaster, lightly massage the skin for approximately 20 seconds to ensure perfect adhesion of the medicated plaster. Do not exceed the recommended doses. \u003ci\u003ePediatric population\u003c\/i\u003e: There is no experience on the use of DICLOREUM UNIDIE in children and therefore its use is not recommended in subjects under 12 years of age (see sections 4.3 and 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo particular storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe plasma levels of ibuprofen achieved after administration of the medicated plaster are much lower than those obtained through systemic administration and therefore the onset of systemic side effects is likely to be much reduced compared to systemic use. However, if medicated plasters are used for a prolonged period of time it is not possible to exclude the possibility of systemic adverse events. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Analgesics, antipyretics and non-steroidal anti-inflammatory drugs (non-selective NSAIDs and selective COX-2 inhibitors), including ibuprofen, can cause potentially serious hypersensitivity reactions in subjects not previously exposed to this type of drugs. These reactions include asthma attacks, skin rashes, allergic rhinitis and anaphylactic-type reactions. Like other NSAIDs, ibuprofen can mask signs of infection. Elderly: Caution should be used when treating elderly patients who are generally more predisposed to adverse events. Asthmatic patients, with obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react more often than other patients to treatment with NSAIDs, with asthma attacks, local inflammation of the skin and mucosa (Quincke's edema) or urticaria. Gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported during treatment with all NSAIDs at any time, with or without warning symptoms or previous history of serious gastrointestinal events. Use caution when administering DICLOREUM UNIDIE in patients with a history of peptic ulcer or gastrointestinal bleeding not secondary to the administration of NSAIDs and in cases of ulcerative colitis and Crohn's disease. Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal haemorrhage) particularly in the initial stages of treatment. Caution should be exercised in patients taking concomitant medications that may increase the risk of ulceration or haemorrhage, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as aspirin (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking DICLOREUM UNIDIE, treatment should be discontinued. It is also not recommended in cases of haemorrhagic diathesis, severe liver or kidney dysfunction and in cases of heart failure. Caution should be exercised in patients with a history of hypertension and\/or mild to moderate congestive heart failure since fluid retention and edema have been reported in association with treatment with NSAIDs. NSAIDs can reduce the effect of diuretics and other antihypertensive drugs (see section 4.5). Ibuprofen may cause water and sodium, potassium retention in patients who have never suffered from kidney disease due to its effects on renal perfusion. This may cause edema or heart failure or hypertension in predisposed patients. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other renal pathological changes. Ibuprofen, like other NSAIDs, can inhibit platelet aggregation and has shown evidence of prolonging bleeding time in healthy subjects. Therefore, patients with coagulation defects or on anticoagulant therapy should be carefully observed. On rare occasions, aseptic meningitis has been observed in patients receiving ibuprofen. Prolonged or repeated use of products for skin use can give rise to local phenomena awareness. Analgesics, antipyretics, non-steroidal anti-inflammatory drugs can cause potentially serious hypersensitivity reactions (anaphylactoid reactions), even in subjects not previously exposed to this type of drugs. The risk of hypersensitivity reactions after taking ibuprofen is greater in subjects who have experienced such reactions after the use of other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and in subjects with bronchial hyperreactivity (asthma), hay fever, nasal polyposis or chronic obstructive respiratory diseases or previous episodes of angioedema. In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. Severe hypersensitivity reactions (e.g. anaphylactic shock) have been observed rarely. In the presence of significant adverse reactions (skin reactions such as exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis) and hypersensitivity reactions it is necessary to immediately discontinue therapy and consult the doctor for the purpose of instituting suitable therapy. Dopo breve terapia senza risultati apprezzabili, consultare il medico. Non c’è esperienza sull’uso di DICLOREUM UNIDIE nei bambini e pertanto se ne sconsiglia l’utilizzo in soggetti età inferiore a 12 anni.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of ibuprofen patches is unlikely to have interactions with other medicines. However, the possibility of competition between absorbed ibuprofen and other drugs with high binding to plasma proteins cannot be excluded. Non utilizzare il prodotto insieme ad altri farmaci per uso orale o locale contenenti ibuprofene od altri FANS.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by reducing the duration of treatment to the shortest possible time needed to control symptoms. Per determinare la frequenza delle reazioni avverse sono stati usati dati provenienti dagli studi clinici sul prodotto. The following convention was adopted for frequency classification: Very common ≥1\/10; Common ≥1\/100 - \u003c1\/10; Uncommon ≥1\/1,000 - \u003c1\/100; Rare ≥1\/10,000 - \u003c1\/1,000; Molto rari \u003c1\/10.000, non nota (non può essere definita sulla base dei dati disponibili). \u003cb\u003eTable 1: \u003c\/b\u003eIncidenza di effetti indesiderati associati al trattamento negli studi clinici controllati.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eComuni - Reazione indesiderata: Secchezza delle fauci, cefalea, disgeusia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Unwanted reaction: Nausea.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eComuni - Reazione indesiderata: Edema facciale, vescicole.\u003c\/p\u003e\n\u003cp\u003eNon nota - Reazione indesiderata: Reazione da farmaco con eosinofilia e sintomi sistemici (sindrome DRESS).\u003c\/p\u003e\n\u003cp\u003ePathologies of the musculoskeletal system and connective tissue.\u003c\/p\u003e\n\u003cp\u003eComuni - Reazione indesiderata: Malessere generale.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eVery Common - Undesirable reaction: Mild erythema.\u003c\/p\u003e\n\u003cp\u003eCommon - Undesirable reaction: Itching, burning, clear erythematous manifestation, skin exfoliation and cracking.\u003c\/p\u003e\n\u003cp\u003eAll adverse events encountered in clinical trials were mild and transient in nature. Side effects reported from literature data\u003c\/p\u003e\n\u003cp\u003eImmune system pathologies.\u003c\/p\u003e\n\u003cp\u003eNon note - Reazione indesiderata: Ipersensibilità locali.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eNot known - Undesirable reaction: Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eNot known - Undesirable reaction: Contact dermatitis.\u003c\/p\u003e\n\u003cp\u003eNot known - Undesirable reaction: Numbness and tingling at the application site.\u003c\/p\u003e\n\u003cp\u003eCases of extensive and serious dermatological lesions such as erythema multiforme, Quincke's edema and, very rarely, bullous reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis have been reported with this type of medicines. Systemic undesirable reactions following the topical use of ibuprofen are unlikely as the plasma levels of ibuprofen detected following the application of DICLOREUM UNIDIE are much lower than those detectable with the systemic administration of ibuprofen-based drugs. However, following applications for long periods of time, beyond the recommended term and failure to comply with contraindications and warnings, it is not possible to exclude the appearance of systemic side effects, especially at a gastrointestinal level (see paragraphs 4.4 and 5.2). \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported. Should systemic side effects occur due to incorrect use or accidental overdose with the product, the general supportive measures to be taken in case of intoxication with non-steroidal anti-inflammatory drugs are recommended. In cases of severe poisoning, metabolic acidosis may occur.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe systemic concentration of ibuprofen, compared to oral formulations, is lower after topical administration. Referring to the experience of treatment with NSAIDs for systemic administration, the following is recommended: \u003cu\u003ePregnancy\u003c\/u\u003e: Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Data obtained from epidemiological studies suggest an increased risk of miscarriage, cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor during early pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk is thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, ibuprofen should not be administered unless strictly necessary. When used by women in the process of conceiving or during the first and second trimester of pregnancy, the dose and duration of treatment should be as low and as short as possible, respectively. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction which may progress to renal failure with oligohydroamnios; the mother and newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, ibuprofen is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e: Ibuprofen is excreted in breast milk: at therapeutic doses during short-term treatment the risk of influencing the newborn seems unlikely, while in case of long-term treatment early weaning should be considered. NSAIDs should be avoided during breast-feeding. \u003cu\u003eFertility\u003c\/u\u003e: The use of ibuprofen may impair female fertility and is not recommended in women attempting to conceive. This effect is reversible upon discontinuation of treatment. In women who have difficulty conceiving or who are under investigation for infertility, discontinuation of ibuprofen treatment should be considered.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies on the effects on the ability to drive and use machines have been performed as DICLOREUM UNIDIE is not expected to interfere with these abilities.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51730207867207,"sku":"037184013","price":18.14,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-dicloreum-unidie-136-mg-5-cerotti-medicati-farmacia-dottor-tili-1213791086.jpg?v=1767140489"},{"product_id":"vegetallumina-antidolo-re-10-50-g-gel","title":"Vegetalumina Antipain 10% 50 g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of bruises, sprains, myalgia, muscle strains, stiff neck.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of gel contains: Active ingredient: Ibuprofen lysine salt 10 g Excipients with known effects: sodium methyl para-oxybenzoate and sodium ethyl para-oxybenzoate, lavender essence (containing allergens). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIsopropanol, hydroxyethylcellulose, sodium methyl paraoxybenzoate, sodium ethyl paraoxybenzoate, glycerol, lavender essence, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Due to the possibility of cross-sensitization, the medicine must not be administered to patients in whom acetylsalicylic acid or other non-steroidal anti-inflammatory drugs have caused asthma, rhinitis, urticaria or other allergic manifestations. - Pregnancy. - Breastfeeding. - Children and adolescents under 14 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e 2-4 applications per day on the painful part. Elderly patients should stick to the minimum dosages indicated above. \u003ci\u003ePediatric population\u003c\/i\u003e There is no data available. \u003cu\u003eMethod of administration\u003c\/u\u003e Apply a thin layer of gel on the area to be treated with a light massage. Use the medicine for the shortest period possible. Wash your hands carefully and thoroughly after application.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special instructions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt is advisable to avoid applying VEGETALLUMINA Antidolore to open wounds or skin lesions. The use of VEGETALLUMINA Antidolore, like any drug that inhibits the synthesis of prostaglandins and cyclooxygenase, is not recommended in women who intend to become pregnant. The administration of VEGETALLUMINA Antidolore must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use of VEGETALLUMINA Antidolore, especially if prolonged, can give rise to local sensitization phenomena: at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity, interrupt treatment and adopt adequate therapeutic measures. To avoid more serious hypersensitivity or photosensitivity phenomena, the patient must not expose himself to direct sunlight, including the solarium, during treatment and in the following two weeks. In case of allergic reactions or more serious adverse reactions (skin reactions, some of which are fatal, such as exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis) it is necessary to immediately suspend therapy at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity (see section 4.8). Patients appear to be at higher risk in the early stages of therapy: the onset of skin reactions occurs in most cases within the first month of treatment. \u003cb\u003eDo not use VEGETALLUMINA Antidolore together with another NSAID or, in any case, do not use more than one NSAID at a time.\u003c\/b\u003e \u003cb\u003eImportant information about some excipients of VEGETALLUMINA Antidolore\u003c\/b\u003e Anti-pain Vegetallumina contains lavender essence which in turn contains citral, citronellol, coumarin, eugenol, Evernia furfuracea extract, Evernia prunastri extract, geraniol, limonene, linalool. Citral, citronellol, coumarin, eugenol, geraniol, limonene, linalool can cause allergic reactions. This medicinal product contains sodium methyl parahydroxybenzoate and sodium ethyl parahydroxybenzoate. Sodium methylhydroxy benzoate and sodium ethylhydroxy benzoate can cause allergic reactions (even delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe paucity of data and the uncertainties relating to their application to the clinical situation do not allow definitive conclusions to be drawn on possible interactions with other drugs for the continuous use of ibuprofen; no clinically relevant interactions have been found with the occasional use of ibuprofen. Bear in mind, in any case, that Ibuprofen can increase the effects of anticoagulants such as warfarin. \u003ci\u003ePediatric population\u003c\/i\u003e There is no data available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Skin reactions with erythema, itching, irritation, sensation of heat or burning and contact dermatitis have been reported with some non-steroidal anti-inflammatory drugs derived from propionic acid for local or transdermal use. Some cases of bullous eruptions of varying severity have also been reported, including Stevens Johnson syndrome, toxic epidermal necrolysis (very rarely) and photosensitivity reactions (frequency not known). \u003ci\u003ePediatric population\u003c\/i\u003e There is no data available. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system of the Italian Medicines Agency at: http:\/\/www.aifa.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eToxicity\u003c\/u\u003e Signs and symptoms of toxicity were generally not observed at doses below 100 mg\/kg in children or adults. However, in some cases supportive treatment may be necessary. Children have been observed to exhibit signs and symptoms of toxicity after ingesting ibuprofen at doses of 400 mg\/kg or greater. \u003cu\u003eSymptoms\u003c\/u\u003e Most patients who have ingested significant amounts of ibuprofen will experience symptoms within 4 to 6 hours. The most commonly reported overdose symptoms include: nausea, vomiting, abdominal pain, lethargy, and drowsiness. Central nervous system (CNS) effects include headache, tinnitus, dizziness, seizures, and loss of consciousness. Nystagmus, metabolic acidosis, hypothermia, renal effects, gastrointestinal bleeding, coma, apnea, diarrhea and CNS and respiratory depression have also been reported rarely. Disorientation, arousal, fainting and cardiovascular toxicity including hypotension, bradycardia and tachycardia have been reported. In cases of significant overdose, renal failure and liver damage are possible. \u003cu\u003eTreatment\u003c\/u\u003e There is no specific antidote for ibuprofen overdose. In case of overdose, symptomatic and supportive treatment is therefore indicated. Particular attention is due to the control of blood pressure, acid-base balance and any gastrointestinal bleeding. Administration of activated charcoal should be considered within one hour of ingesting a potentially toxic quantity. Alternatively, in adults, gastric lavage should be considered within one hour of ingesting a potentially life-threatening overdose. Adequate diuresis must be ensured and renal and hepatic functions must be closely monitored. The patient must remain under observation for at least four hours following ingestion of a potentially toxic amount of drug. Any occurrence of frequent or prolonged convulsions should be treated with intravenous diazepam. Depending on the patient's clinical condition, other support measures may be necessary. For more information, contact your local poison control center.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of VEGETALLUMINA Antidolore is contraindicated during pregnancy and breastfeeding. \u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo\/fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the genetic organ period. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose • the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; • the mother and newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVEGETALLUMINA Antipain does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Pietrasanta Pharma","offers":[{"title":"Default Title","offer_id":51730211176775,"sku":"041734017","price":9.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/pietrasanta-pharma-spa-vegetallumina-antidolo-re-10-50-g-gel-farmacia-dottor-tili-1213791034.jpg?v=1767164627"},{"product_id":"flectorartro-1-100-g-gel-in-contenitore-pressurizzato","title":"FlectorArtro 1% 100g gel in pressurized container","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic local relief of pain and inflammatory states caused by post-traumatic injuries, such as contusions, sprains and tendinitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of gel contains 1 g of diclofenac sodium in the form of diclofenac epolamine. Excipients with known effects: propylene glycol, methyl benzoate. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSoy Lecithin, Macrogolglycerol Hydroxystearate, Macrogol Stearate, Carbomer, Sodium Hydroxide, Isopropyl Alcohol, Fragrance (Floral PH–Y containing Benzyl Acetate, Phenylethyl Alcohol, Hydroxycitronellal, Paraguayan Petitgrain Oil, Cinnamic Alcohol, Propylene Glycol and Methyl Benzoate), Purified Water. Compressed air (for pressure vessel only)\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine is contraindicated in the following cases: – Hypersensitivity to diclofenac, acetylsalicylic acid (aspirin) or other NSAIDs. – Hypersensitivity to any other component of the gel. – Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by the action of acetylsalicylic acid or non-steroidal anti-inflammatory drugs (NSAIDs). – Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. – Starting from the third trimester of pregnancy (see section 4.6). – Use in children and adolescents under 15 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. Only for adults and adolescents over 15 years of age. Based on the size of the affected area to be treated, apply 2 – 4 g of gel 2 – 4 times a day for a maximum treatment period of two weeks. After application, wash your hands, unless they are the treated area. In the absence of improvement or in case of worsening of the condition after 4 days of treatment, consult your doctor or pharmacist. \u003ci\u003eElderly\u003c\/i\u003e The dosage indicated for adults may be valid. See also paragraph 4.4 \u003ci\u003eChildren and adolescents under 15 years of age \u003c\/i\u003e There are insufficient efficacy and safety data available for children and adolescents under 15 years of age (see also section 4.3). In subjects aged 15 years and older, the patient\/parents of the patient should consult the doctor if treatment with this medicine is necessary for a period of more than 7 days as analgesic therapy or in case of worsening of symptoms. \u003ci\u003ePatients with hepatic or renal insufficiency \u003c\/i\u003e For the use of Flectorartro 1% gel in patients with hepatic or renal insufficiency see section 4.4.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by administering the lowest effective dose for the shortest duration necessary to control symptoms, without exceeding a maximum period of two weeks (See sections 4.2 and 4.8). The possibility of systemic adverse events produced by the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see product information relating to other systemic forms of diclofenac). Although the onset of effects at a systemic level is very rare, caution should be used when using the gel in patients with renal, cardiac or hepatic impairment, previous history of peptic ulcer or inflammatory bowel disease or haemorrhagic diathesis. Nonsteroidal anti-inflammatory drugs should be used with particular caution in elderly patients, who are more predisposed to the onset of adverse events. Diclofenac for topical use should only be applied to intact, non-broken skin, not to lesions or open wounds. It must not come into contact with the eyes or mucous membranes and must not be ingested. Stop treatment if you develop a skin rash after applying the product. Diclofenac for topical use can be used with non-occlusive dressings, but should not be used with non-breathable occlusive dressings. Patients should be informed about the contraindication to direct sun exposure and artificial UV rays in order to reduce the risk of photosensitivity. The use of gloves is recommended for the physiotherapist. Diclofenac for topical use in gel contains propylene glycol which may cause mild localized skin irritation in some subjects. The presence of methyl benzoate causes irritation of the skin, eyes and mucous membranes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac from topical application of the gel is very low, interactions with other medicinal products are unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are classified by frequency, the highest frequency first, with the following convention: very common: (\u003e1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003eNot known: Anaphylactic-type reaction.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Pustular eruption.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (allergic and contact), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac for topical application is very low compared to the levels of the active ingredient present in the plasma after taking oral diclofenac. The probability of systemic side effects (such as gastrointestinal (e.g. bleeding), hepatic or renal disorders) is therefore very low after topical application compared to the frequency of side effects associated with taking oral diclofenac. However, the use of diclofenac on a large skin area may lead to the onset of systemic side effects. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of diclofenac for topical use makes the risk of overdose very unlikely. However, side effects similar to those observed after overdose of diclofenac tablets are to be expected in case of accidental ingestion of diclofenac for topical use (1 tube of 100 g contains the equivalent of 1000 mg of diclofenac sodium). In case of accidental ingestion resulting in significant systemic adverse effects, the therapeutic measures normally adopted for the treatment of poisoning by non-steroidal anti-inflammatory drugs should be used. The hypothesis of gastric decontamination and the use of activated charcoal will also be evaluated, especially within a short time after ingestion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy \u003c\/u\u003e The systemic concentration of diclofenac epolamine is lower after topical administration, compared to oral formulations. In relation to the experience acquired in the context of treatment with NSAIDs for systemic use, the following is recommended: Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiovascular malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac epolamine should not be administered unless strictly necessary. If diclofenac epolamine is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose the fetus to: – cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); – renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, close to birth, to: – possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; – inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated starting from the third trimester of pregnancy. \u003cu\u003eBreastfeeding \u003c\/u\u003e Similar to other NSAIDs, diclofenac is passed into breast milk in small quantities. However, at therapeutic doses of Flectorarthro 1% gel, no effects on the infant are expected. Since no controlled studies have been conducted on breastfeeding women, the product should be used during breastfeeding only under medical supervision. In this case, Flectorarthro 1% gel should not be applied to the breast or to any large area of ​​skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCutaneous application of topical diclofenac does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Ibsa","offers":[{"title":"Default Title","offer_id":51730211242311,"sku":"041472046","price":13.86,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ibsa-farmaceutici-italia-srl-flectorartro-1-100-g-gel-in-contenitore-pressurizzato-farmacia-dottor-tili-1213791032.jpg?v=1767164589"},{"product_id":"dicloreum-actigel-1-100-g-gel","title":"Dicloreum Actigel 1% 100 g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor the local treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of \u003ci\u003egel\u003c\/i\u003e contain: \u003ci\u003eActive ingredient\u003c\/i\u003e: diclofenac hydroxyethylpyrrolidine 1.32 g – equal to 1.0 g of diclofenac sodium. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003emacrogols, macrogol stearate, cetyl stearyl–2–ethylhexanoate, carbomers, trolamine, isopropyl alcohol, fragrance, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIndividual hypersensitivity confirmed towards the components of the product. Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs), as well as isopropanol. Contraindicated in the third trimester of pregnancy (see section 4.6 \u003ci\u003eFertility, pregnancy and breastfeeding\u003c\/i\u003e). \u003ci\u003e \u003cu\u003eChildren and adolescents\u003c\/u\u003e \u003c\/i\u003e Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003cu\u003eAdults over 18 years old\u003c\/u\u003e:\u003c\/i\u003e Apply DICLOREUM ACTIGEL 3 or 4 times a day on the area to be treated, rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 2–4 g of DICLOREUM ACTIGEL (a quantity varying in size between a cherry and a walnut) are sufficient to treat an area of 400–800 cm². After application, wash your hands, otherwise they will also be treated with the gel. Warning: use only for short treatment periods. \u003ci\u003e \u003cu\u003eAdolescents aged 14 to 18\u003c\/u\u003e:\u003c\/i\u003e Apply DICLOREUM ACTIGEL 3 or 4 times a day on the area to be treated, rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 2–4 g of DICLOREUM ACTIGEL (a quantity varying in size between a cherry and a walnut) are sufficient to treat an area of 400–800 cm². After application, wash your hands, otherwise they will also be treated with the gel. If this product is needed for more than 7 days to relieve pain or if symptoms worsen, consult a doctor. \u003ci\u003e \u003cu\u003eChildren under 14 years old\u003c\/u\u003e:\u003c\/i\u003e Insufficient data are available on efficacy and safety in children and adolescents under 14 years of age (see also section 4.3 Contraindications). Therefore, the use of DICLOREUM ACTIGEL is contraindicated in children under 14 years of age. \u003ci\u003e \u003cu\u003eElderly\u003c\/u\u003e:\u003c\/i\u003e The usual dosage for adults can be used\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 30°C\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see the summary of product characteristics of systemic forms of diclofenac). DICLOREUM ACTIGEL must not be applied to skin wounds or open lesions, but only to intact skin. Avoid the preparation coming into contact with the eyes and mucous membranes. The gel should not be swallowed. In elderly patients and\/or with gastric problems, the concomitant use of systemic anti-inflammatory drugs is not recommended. Asthmatic patients, with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to antirheumatic treatment carried out with NSAIDs more often than other patients. The use, especially if prolonged, of other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Discontinue treatment if skin rash develops after application of the product. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eKeep the medicine out of the sight and reach of children.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough bioavailability studies show that an interaction with other drugs is unlikely, in high-dose and prolonged treatments the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins should be kept in mind.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c1\/10); uncommon (≥ 1\/1,000, \u003c1\/100); rare (≥ 1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: cannot be estimated from available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction.\u003c\/p\u003e\n\u003cp\u003eThe use of the product in combination with other drugs containing diclofenac can give rise to phenomena of hypersensitivity to light, skin rash with the formation of vesicles, eczema, erythema and skin reactions with severe evolution (Stevens-Johnson syndrome, Lyell syndrome).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of topical diclofenac makes overdose very unlikely. However, side effects similar to those seen after an overdose of diclofenac tablets can be expected if topical diclofenac is inadvertently ingested (1 50 g tube contains the equivalent of 500 mg of diclofenac sodium). In case of accidental ingestion, which gives rise to significant systemic side effects, the general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Gastric decontamination and the use of activated charcoal should be taken into consideration, especially within a short time after ingestion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: • cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); • renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: • possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; • inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of DICLOREUM ACTIGEL no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, DICLOREUM ACTIGEL must not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt does not interfere with the ability to drive and use machines.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51730211832135,"sku":"035450028","price":14.23,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-dicloreum-actigel-1-100-g-gel-farmacia-dottor-tili-1213791015.jpg?v=1767164968"},{"product_id":"voltaren-emulgel-1-gel-60-g","title":"Voltaren Emulgel 1% Gel 60 g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons and ligaments (such as tendonitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e contain 1.16 g of diclofenac diethylammonium, equivalent to 1 g of diclofenac sodium. Excipients with known effects: propylene glycol (50 mg\/g gel); benzyl benzoate (1 mg\/g gel); Cream 45 perfume. For the complete list of excipients, see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDiethylamine, carbomers, macrogol cetostearyl ether, cocoyl caprylocaprate, isopropyl alcohol, liquid paraffin, \u003cb\u003eCream 45 perfume\u003c\/b\u003e (contains \u003cb\u003ebenzyl benzoate\u003c\/b\u003e), \u003cb\u003epropylene glycol\u003c\/b\u003e, purified water\u003cb\u003e.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Patients in whom asthma, angioedema, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Third trimester of pregnancy. \u003cu\u003eChildren and adolescents\u003c\/u\u003e: Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAdults over 18 years:\u003c\/b\u003e Apply \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e 3 or 4 times a day on the area to be treated, rubbing lightly. The quantity to be applied depends on the size of the affected part. For example 2-4 g of \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of 400-800 cm². After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 1% to dry before showering or bathing. Warning: use only for short treatment periods. \u003cb\u003eAdolescents aged 14 to 18\u003c\/b\u003e Apply Voltaren Emulgel \u003ci\u003e1% gel\u003c\/i\u003e 3 or 4 times a day on the area to be treated, rubbing lightly. The quantity to be applied depends on the size of the affected part. For example 2-4 g of Voltaren Emulgel \u003ci\u003e1% gel\u003c\/i\u003e (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of 400-800 cm². After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 1% to dry before showering or bathing. If this product is needed for more than 7 days for pain relief or if symptoms worsen, consult a doctor. \u003cb\u003eChildren under 14 years:\u003c\/b\u003e Insufficient data are available on efficacy and safety in children and adolescents under 14 years (see also section 4.3 Contraindications). Therefore, the use of Voltaren Emulgel \u003ci\u003e1% gel\u003c\/i\u003e It is contraindicated in children under six 14 years of age. \u003cb\u003eElderly (over 65 years):\u003c\/b\u003e The usual dosage for adults can be used.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eTube of 60 g, 100 g, 120 g, 150 g gel and 120 g 1% gel with applicator cap\u003c\/u\u003e: Store below 30°C. \u003cu\u003e50 g pressurized container\u003c\/u\u003e: Store below 30°C. Warning: the container is under pressure: store away from direct sunlight, do not puncture or burn the container, even after use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see the summary of product characteristics of systemic forms of diclofenac\u003ci\u003e).\u003c\/i\u003e Topical diclofenac should only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e contains 200 mg of propylene glycol per dose (4 g) equivalent to 50 mg\/g and 4 mg of benzyl benzoate per dose (4 g) equivalent to 1 mg\/g which may cause skin irritation. \u003cb\u003e \u003ci\u003eVoltaren Emulgel 1% gel contains Cream 45 perfume, an aroma which in turn contains benzyl alcohol, citral, citronellol, coumarin, d-limonene, eugenol, farinasol, geraniol, linalool which may cause allergic reactions.\u003c\/i\u003e \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, such interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: very common (≥1\/10), common (≥1\/100, \u003c1\/10); uncommon (≥ 1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction, allergic reactions.\u003c\/p\u003e\n\u003cp\u003eNot known: Burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of topical diclofenac makes overdose very unlikely. However side effects similar to those seen after an overdose of diclofenac tablets\u003ci\u003e,\u003c\/i\u003e can be expected if topical diclofenac is ingested (1 60 g tube contains the equivalent of 600 mg of sodium diclofenac). In case of ingestion resulting in significant systemic side effects, the general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Further treatment modalities, within the short term of ingestion, should take into account clinical indications or the recommendation of the poison control center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e it must not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCutaneous application of topical diclofenac does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":53137878024519,"sku":"034548178","price":7.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/novartis-farma-spa-Voltaren_Emulgel_1_Gel_60_g-farmacia-dottor-tili-1216497345.jpg?v=1774447396"},{"product_id":"muscoril-dolore-gel-20-mg-g-dolori-muscolari-100-g","title":"Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g","description":"\u003cp\u003e\u003cstrong\u003eMuscoril Pain Gel 20 mg\/g Muscle Pain 100 g\u003c\/strong\u003e is a medicine for cutaneous use based on \u003cstrong\u003ediclofenac\u003c\/strong\u003e, an active ingredient belonging to the class of \u003cstrong\u003enon-steroidal anti-inflammatory drugs (NSAIDs)\u003c\/strong\u003e, known for its properties \u003cstrong\u003eanti-inflammatory and analgesic\u003c\/strong\u003e. The gel formulation is designed to be applied directly to the painful area, promoting a targeted action useful for reducing pain, inflammation and swelling in muscle and joint tissues.\u003c\/p\u003e\n\u003cp\u003eThis medicine is indicated for \u003cstrong\u003elocal symptomatic treatment of muscle pain\u003c\/strong\u003e caused by trauma or overload, such as \u003cstrong\u003emuscle strains, sprains and bruises\u003c\/strong\u003e, frequent situations during sporting activity or following small daily accidents. The action of diclofenac helps to counteract local inflammatory processes, helping to improve the comfort and mobility of the affected area.\u003c\/p\u003e\n\u003cp\u003eThe gel consistency allows for a \u003cstrong\u003eeasy application on the skin\u003c\/strong\u003e and rapid absorption without excessive grease, making the product practical to use in the daily routine. Muscoril Pain Gel is indicated for \u003cstrong\u003eadults and adolescents aged 14 and over\u003c\/strong\u003e and represents a useful solution for the targeted treatment of \u003cstrong\u003elocalized muscle pain\u003c\/strong\u003e and discomfort associated with minor trauma.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g used? What is it for?\u003c\/h3\u003e\u003cp\u003eMUSCORIL PAIN contains the active ingredient diclofenac which belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).\u003c\/p\u003e\u003cp\u003eMUSCORIL PAIN is indicated:\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eFor adults and adolescents aged 14 and over\u003c\/strong\u003e\u003cbr\u003eFor the local symptomatic treatment of pain associated with acute muscle strains, sprains or bruises following impact trauma, such as sports injuries and accidents.\u003c\/p\u003e\u003cp\u003eFor adolescents aged 14 years and older the medicine is indicated for short-term treatment.\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g?\u003c\/h3\u003e\u003cp\u003e100 g of gel contain: active ingredient diclofenac 20 mg\/g.\u003c\/p\u003e\u003cp\u003eFor the complete list of excipients, see the information leaflet in the package.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g?\u003c\/h3\u003e\u003cp\u003eApply the gel to the affected area, massaging lightly until completely absorbed.\u003c\/p\u003e\u003cp\u003eAfter application, wash your hands, unless they are the site of the treatment.\u003c\/p\u003e\u003cp\u003eThe medicine is indicated for adults and adolescents aged 14 years and older.\u003c\/p\u003e\u003cp\u003eIn adolescents the medicine is indicated for short-term treatment.\u003c\/p\u003e\u003cp\u003eConsult your doctor if symptoms worsen or do not improve within 3 to 5 days.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eDo not use MUSCORIL DOLORE:\u003c\/p\u003e\u003cp\u003e- if you are allergic to diclofenac or any of the other ingredients of this medicine;\u003cbr\u003e- if you have developed attacks of asthma, hives, runny nose (acute rhinitis) after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs);\u003cbr\u003e- on open wounds, inflammation or skin infections, on eczema or on mucous membranes;\u003cbr\u003e- if you are in the last 3 months of pregnancy;\u003cbr\u003e- in children and adolescents under 14 years of age.\u003c\/p\u003e\u003cp\u003eLike all medicines, this medicine can cause side effects, although not everybody gets them.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eRare side effects\u003c\/strong\u003e (may affect up to 1 in 1,000 people)\u003c\/p\u003e\u003cp\u003e• Inflammation of the skin with blisters (bullous dermatitis).\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eVery rare side effects\u003c\/strong\u003e (may affect up to 1 in 10,000 people)\u003c\/p\u003e\u003cp\u003e• Asthma;\u003cbr\u003e• Swelling of the face, lips, tongue or throat (angioedema).\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eMunicipalities\u003c\/strong\u003e (may affect up to 1 in 10 people)\u003c\/p\u003e\u003cp\u003e• Rash, redness of the skin (erythema), dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eUncommon\u003c\/strong\u003e (may affect up to 1 in 100 people)\u003c\/p\u003e\u003cp\u003e• Scaling, dehydration of the skin, edema.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eVery rare\u003c\/strong\u003e (may affect up to 1 in 10,000 people)\u003c\/p\u003e\u003cp\u003e• Skin rash with pustules;\u003cbr\u003e• Gastrointestinal disorders;\u003cbr\u003e• Hypersensitivity reactions, including urticaria;\u003cbr\u003e• Photosensitivity reactions.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eFrequency not known\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003e• Burning sensation at the application site.\u003c\/p\u003e\u003cp\u003eWhen MUSCORIL DOLORE is applied to a large area of ​​skin and for a prolonged period, the possibility of systemic side effects similar to those that may appear after the systemic administration of medicines containing diclofenac cannot be excluded.\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g?\u003c\/h3\u003e\u003cp\u003eTalk to your doctor or pharmacist before using MUSCORIL DOLORE.\u003c\/p\u003e\u003cp\u003eIf you suffer from asthma, allergic rhinitis, swelling of the nasal mucosa (nasal polyps) or chronic obstructive pulmonary disease, chronic respiratory tract infections (associated in particular with symptoms similar to allergic rhinitis), you are more exposed to asthma attacks, local swelling of the skin or mucous membranes (Quincke's edema) and urticaria.\u003c\/p\u003e\u003cp\u003eWhen MUSCORIL DOLORE is applied to a large area of ​​skin and for a prolonged period, the possibility of systemic side effects cannot be excluded.\u003c\/p\u003e\u003cp\u003eApply MUSCORIL DOLORE only on intact, healthy and wound-free skin. Avoid contact with eyes and oral mucous membranes. The gel should not be swallowed.\u003c\/p\u003e\u003cp\u003eAfter applying the gel to the skin, you can use a breathable (non-occlusive) bandage, but you must first let the gel dry on the skin for a few minutes.\u003c\/p\u003e\u003cp\u003eDo not use it with occlusive bandages that do not let air pass.\u003c\/p\u003e\u003cp\u003eConsult your doctor if symptoms worsen or do not improve within 3 to 5 days.\u003c\/p\u003e\u003cp\u003eThe use of MUSCORIL DOLORE should be stopped if you develop a skin rash.\u003c\/p\u003e\u003cp\u003eAvoid exposure to sunlight, including sunlamps, while using this medicine.\u003c\/p\u003e\u003cp\u003eNecessary precautions should be taken to prevent children from touching the area to which the gel is applied.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g stored?\u003c\/h3\u003e\u003cp\u003eStore the medicine according to the instructions on the package.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g?\u003c\/h3\u003e\u003cp\u003e100 g\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Doc Generici","offers":[{"title":"Default Title","offer_id":53463748018503,"sku":"051378026","price":17.58,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/doc-generici-srl-muscoril-dolore-gel-20-mg-g-dolori-muscolari-100-g-farmacia-dottor-tili-1226760408.webp?v=1774447393"},{"product_id":"muscoril-dolore-gel-20-mg-g-dolori-muscolari-60-g","title":"Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g","description":"\u003cp\u003e\u003cstrong\u003eMuscoril Pain Gel 20 mg\/g Muscle Pain 60 g\u003c\/strong\u003e is a medicine for cutaneous use based on diclofenac, an active ingredient belonging to the class of non-steroidal anti-inflammatory drugs (NSAIDs), known for its anti-inflammatory and analgesic properties. The gel formulation is designed to be applied directly to the painful area, promoting a targeted action useful for reducing pain, inflammation and swelling in muscle and joint tissues.\u003c\/p\u003e\n\u003cp\u003eThis medicine is indicated for the local symptomatic treatment of muscle pain caused by trauma or overload, such as muscle strains, sprains and bruises, frequent situations during sporting activity or following small daily accidents. The action of diclofenac helps to counteract local inflammatory processes, helping to improve the comfort and mobility of the affected area.\u003c\/p\u003e\n\u003cp\u003eThe gel consistency allows for easy application on the skin and rapid absorption without being excessively greasy, making the product practical to use in your daily routine. Muscoril Pain Gel is indicated for adults and adolescents aged 14 and over and represents a useful solution for the targeted treatment of localized muscle pain and discomfort associated with minor trauma.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g used? What is it for?\u003c\/h3\u003e\u003cp\u003eMUSCORIL PAIN contains the active ingredient diclofenac which belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).\u003c\/p\u003e\u003cp\u003eMUSCORIL PAIN is indicated:\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eFor adults and adolescents aged 14 and over\u003c\/strong\u003e\u003cbr\u003eFor the local symptomatic treatment of pain associated with acute muscle strains, sprains or bruises following impact trauma, such as sports injuries and accidents.\u003c\/p\u003e\u003cp\u003eFor adolescents aged 14 years and older the medicine is indicated for short-term treatment.\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g?\u003c\/h3\u003e\u003cp\u003e100 g of gel contain: active ingredient diclofenac 20 mg\/g.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eFor the complete list of excipients, see the information leaflet in the package.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g?\u003c\/h3\u003e\u003cp\u003eApply the gel to the affected area, massaging lightly until completely absorbed.\u003c\/p\u003e\u003cp\u003eAfter application, wash your hands, unless they are the site of the treatment.\u003c\/p\u003e\u003cp\u003eThe medicine is indicated for adults and adolescents aged 14 years and older.\u003c\/p\u003e\u003cp\u003eIn adolescents the medicine is indicated for short-term treatment.\u003c\/p\u003e\u003cp\u003eConsult your doctor if symptoms worsen or do not improve within 3 to 5 days.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eDo not use MUSCORIL DOLORE:\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eif you are allergic to diclofenac or any of the other ingredients of this medicine;\u003c\/li\u003e\n\u003cli\u003eif you have developed attacks of asthma, hives, runny nose (acute rhinitis) after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs);\u003c\/li\u003e\n\u003cli\u003eon open wounds, inflammation or skin infections, on eczema or on mucous membranes;\u003c\/li\u003e\n\u003cli\u003eif you are in the last 3 months of pregnancy;\u003c\/li\u003e\n\u003cli\u003ein children and adolescents under 14 years.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eLike all medicines, this medicine can cause side effects, although not everybody gets them.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eRare side effects\u003c\/strong\u003e (may affect up to 1 in 1,000 people)\u003c\/p\u003e\u003cul\u003e\u003cli\u003eInflammation of the skin with blisters (bullous dermatitis).\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eVery rare side effects\u003c\/strong\u003e (may affect up to 1 in 10,000 people)\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eAsthma;\u003c\/li\u003e\n\u003cli\u003eSwelling of the face, lips, tongue or throat (angioedema).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eMunicipalities\u003c\/strong\u003e (may affect up to 1 in 10 people)\u003c\/p\u003e\u003cul\u003e\u003cli\u003eRash, redness of the skin (erythema), dermatitis (including contact dermatitis), pruritus.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eUncommon\u003c\/strong\u003e (may affect up to 1 in 100 people)\u003c\/p\u003e\u003cul\u003e\u003cli\u003eScaling, skin dehydration, edema.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eVery rare\u003c\/strong\u003e (may affect up to 1 in 10,000 people)\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSkin rash with pustules;\u003c\/li\u003e\n\u003cli\u003eGastrointestinal disorders;\u003c\/li\u003e\n\u003cli\u003eHypersensitivity reactions, including urticaria;\u003c\/li\u003e\n\u003cli\u003ePhotosensitivity reactions.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eFrequency not known\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\u003cli\u003eBurning sensation at the application site.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eWhen MUSCORIL DOLORE is applied to a large area of ​​skin and for a prolonged period, the possibility of systemic side effects similar to those that may appear after the systemic administration of medicines containing diclofenac cannot be excluded.\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g?\u003c\/h3\u003e\u003cp\u003eTalk to your doctor or pharmacist before using MUSCORIL DOLORE.\u003c\/p\u003e\u003cp\u003eIf you suffer from asthma, allergic rhinitis, swelling of the nasal mucosa (nasal polyps) or chronic obstructive pulmonary disease, chronic respiratory tract infections (associated in particular with symptoms similar to allergic rhinitis), you are more exposed to asthma attacks, local swelling of the skin or mucous membranes (Quincke's edema) and urticaria.\u003c\/p\u003e\u003cp\u003eWhen MUSCORIL DOLORE is applied to a large area of ​​skin and for a prolonged period, the possibility of systemic side effects cannot be excluded.\u003c\/p\u003e\u003cp\u003eApply MUSCORIL DOLORE only on intact, healthy and wound-free skin. Avoid contact with eyes and oral mucous membranes. The gel should not be swallowed.\u003c\/p\u003e\u003cp\u003eAfter applying the gel to the skin, you can use a breathable (non-occlusive) bandage, but you must first let the gel dry on the skin for a few minutes.\u003c\/p\u003e\u003cp\u003eDo not use it with occlusive bandages that do not let air pass.\u003c\/p\u003e\u003cp\u003eConsult your doctor if symptoms worsen or do not improve within 3 to 5 days.\u003c\/p\u003e\u003cp\u003eThe use of MUSCORIL DOLORE should be stopped if you develop a skin rash.\u003c\/p\u003e\u003cp\u003eAvoid exposure to sunlight, including sunlamps, while using this medicine.\u003c\/p\u003e\u003cp\u003eNecessary precautions should be taken to prevent children from touching the area to which the gel is applied.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g stored?\u003c\/h3\u003e\u003cp\u003eStore the medicine according to the instructions on the package.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g?\u003c\/h3\u003e\u003cp\u003e60 g\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Doc Generici","offers":[{"title":"Default Title","offer_id":53463748280647,"sku":"051378014","price":13.86,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/doc-generici-srl-muscoril-dolore-gel-20-mg-g-dolori-muscolari-60-g-farmacia-dottor-tili-1226785823.jpg?v=1773164828"},{"product_id":"muscoridol-5-cerotti-medicati-dolore-muscolare-180-mg","title":"Muscoridol 5 Medicated Patches for Muscle Pain 180 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal symptomatic treatment of rheumatic or traumatic pain and inflammation of joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach medicated plaster measuring 10 cm x 14 cm contains a total of 180 mg of diclofenac epolamine equivalent to 140 mg of diclofenac sodium. \u003cu\u003eExcipients with known effects:\u003c\/u\u003e methyl parahydroxybenzoate (E218): 14 mg; propyl parahydroxybenzoate (E216): 7 mg; propylene glycol: 420 mg; referring to the quantity per patch. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBacking layer: non-woven polyester backing. Adhesive layer (active gel): gelatin, povidone (K90), liquid sorbitol (non-crystallizable), heavy kaolin, titanium dioxide (E171), propylene glycol, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), disodium edetate, tartaric acid, aluminum glycinate, sodium carmellose, sodium polyacrylate, 1,3-butylene glycol, polysorbate 80, purified water. Protective layer: polypropylene film.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product is contraindicated in the following cases: - Hypersensitivity to diclofenac, acetylsalicylic acid, other analgesics or other non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients listed in section 6.1. - Patients who have had asthma attacks, urticaria or acute rhinitis triggered by acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. - Third trimester of pregnancy (see section 4.6). - Patients with active peptic ulcer. - Children and adolescents under the age of 16.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. \u003cu\u003eDosage\u003c\/u\u003e One (1) patch on the most painful area once or twice a day. \u003cu\u003eDuration of administration\u003c\/u\u003e Zaranny should be used for the shortest time possible. The maximum duration of treatment is 14 consecutive days. Advise the patient to consult their doctor if they do not experience improvement following the recommended treatment period (see section 4.4). \u003cu\u003eElderly\u003c\/u\u003e This medicine should be used with caution in elderly patients as they are more predisposed to side effects (see section 4.4). \u003cu\u003ePediatric population (Children and adolescents under 16 years old)\u003c\/u\u003e The use of this medicated plaster is not recommended since there are insufficient data available on the safety and efficacy of the medicine in children and adolescents under 16 years of age (see section 4.3). In adolescents aged 16 years and older, if the product is needed for a treatment period longer than 7 days for pain relief or if symptoms worsen, the patient\/parents of the adolescent are advised to consult a doctor, as re-evaluation is necessary. \u003cu\u003ePatients with hepatic or renal insufficiency\u003c\/u\u003e For the use of Zaranny in patients with hepatic or renal insufficiency see section 4.4. \u003cu\u003eMethod of administration\u003c\/u\u003e Cut the bag containing the medicated plaster as indicated. Remove a medicated plaster, remove the plastic film used to protect the adhesive surface and apply the plaster to the joint or painful surface. If necessary, the plaster can be held in place using an elastic mesh bandage. Carefully close the envelope with the sliding closure. The patch must be used whole.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine does not require any particular storage temperature.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- The medicated plaster must only be applied to intact and healthy skin and must not be applied to damaged skin or open wounds and must not be applied when bathing or showering. - The medicated plaster must not come into contact with or be applied to the mucous membranes or eyes. - Do not use with an occlusive dressing that does not let air pass. - Treatment must be stopped immediately if a rash develops after applying the medicated plaster. - Do not administer simultaneously, topically or systemically, another medicinal product based on diclofenac or other NSAIDs. - The possibility of systemic adverse events produced by the application of topical diclofenac cannot be excluded if the preparation is used on a large skin surface and for a prolonged period (see product information relating to other systemic forms of diclofenac). Although systemic effects may be minimal, the patch should be used with caution in patients with impaired renal, cardiac or hepatic function, a history of peptic ulcer, intestinal inflammation or haemorrhagic diathesis. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients, as they are more susceptible to the onset of side effects. - Patients should be advised not to expose themselves to direct sunlight or sun lamps for approximately one day after removing the medicated plaster in order to reduce the risk of photosensitivity. - The medicated plaster should be used with caution in patients with asthma, chronic bronchial obstructive disease, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) who may react with asthma attacks, local inflammation of the skin or mucous membranes (Quincke's edema), urticaria or acute rhinitis after treatment with acetylsalicylic acid or other non-steroidal anti-inflammatory agents more often than other patients (see section 4.3). - In order to minimize the occurrence of side effects, it is recommended to use the lowest effective dose for the shortest duration necessary to control symptoms, without exceeding the approved maximum of 14 days (see sections 4.2 and 4.8). - The use, especially if prolonged, of this as well as other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. - Although systemic absorption is minimal, however the use of the medicated plaster, as of any drug that inhibits prostaglandin synthesis and cyclooxygenase, is not recommended in women intending to become pregnant (see section 4.6). - The administration of the diclofenac-based medicated plaster must be suspended in women who have fertility problems or who are undergoing fertility investigations (see section 4.6). This medicine contains \u003cb\u003emethyl parahydroxybenzoate\u003c\/b\u003e e \u003cb\u003epropyl parahydroxybenzoate\u003c\/b\u003e. They can cause allergic reactions (even delayed); This medicine contains 420 mg of \u003cb\u003epropylene glycol\u003c\/b\u003e per patch.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible. Clinical investigations carried out with the diclofenac-based medicated plaster, used in conjunction with other steroidal and non-steroidal anti-inflammatory drugs (salazopyrin, hydroxyquinoline, etc.), have not highlighted any interaction phenomena. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs (see section 4.8) is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions are listed by frequency, the most frequent first, using the following convention: very common (\u003e1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Pustular rash.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioedema, anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eUncommon: Petechiae.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eNot known: Burning sensation at the application site.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003eUncommon: Feeling hot.\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac is very low compared to the plasma levels measured after oral intake of diclofenac and the probability of systemic side effects (such as gastric, hepatic and renal disorders) is very low compared to the frequency of side effects associated with oral use of diclofenac. However, if Zaranny is used on large skin surfaces and for long periods of time, the appearance of systemic side effects is possible, especially at the gastrointestinal level due to the amount of active ingredient that is absorbed. The use of the product in combination with other drugs containing diclofenac must be avoided as it can give rise to phenomena of hypersensitivity to light, skin rash with vesicle formation, eczema, erythema and, in rare cases, severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome) (see paragraphs 4.4 and 4.5). \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported with diclofenac medicated plasters. Should systemic side effects occur due to incorrect use or accidental overdose (e.g. in children) with the product, the general supportive measures to be taken in case of intoxication with non-steroidal anti-inflammatory drugs are recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e The systemic concentration of diclofenac, compared to oral formulations, is lower after topical administration. Referring to the experience of treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may have negative effects on pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk has been thought to increase with dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligohydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of diclofenac medicated plaster, no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, Zaranny should not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4). \u003cu\u003eFertility\u003c\/u\u003e The administration of the medicated plaster must be suspended in women who have fertility problems or who are undergoing fertility investigations.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe application of diclofenac medicated plasters does not alter the ability to drive vehicles and use machinery.\u003c\/p\u003e","brand":"Doc Generici","offers":[{"title":"Default Title","offer_id":53495604248903,"sku":"045951011","price":9.65,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/doc-generici-srl-muscoridol-5-cerotti-medicati-dolore-muscolare-180-mg-farmacia-dottor-tili-1226919704.webp?v=1774447392"},{"product_id":"muscoridol-10-cerotti-medicati-dolore-muscolare-180-mg","title":"Muscoridol 10 Medicated Patches for Muscle Pain 180 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal symptomatic treatment of rheumatic or traumatic pain and inflammation of joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach medicated plaster measuring 10 cm x 14 cm contains a total of 180 mg of diclofenac epolamine equivalent to 140 mg of diclofenac sodium. \u003cu\u003eExcipients with known effects:\u003c\/u\u003e methyl parahydroxybenzoate (E218): 14 mg; propyl parahydroxybenzoate (E216): 7 mg; propylene glycol: 420 mg; referring to the quantity per patch. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBacking layer: non-woven polyester backing. Adhesive layer (active gel): gelatin, povidone (K90), liquid sorbitol (non-crystallizable), heavy kaolin, titanium dioxide (E171), propylene glycol, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), disodium edetate, tartaric acid, aluminum glycinate, sodium carmellose, sodium polyacrylate, 1,3-butylene glycol, polysorbate 80, purified water. Protective layer: polypropylene film.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product is contraindicated in the following cases: - Hypersensitivity to diclofenac, acetylsalicylic acid, other analgesics or other non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients listed in section 6.1. - Patients who have had asthma attacks, urticaria or acute rhinitis triggered by acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. - Third trimester of pregnancy (see section 4.6). - Patients with active peptic ulcer. - Children and adolescents under the age of 16.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. \u003cu\u003eDosage\u003c\/u\u003e One (1) patch on the most painful area once or twice a day. \u003cu\u003eDuration of administration\u003c\/u\u003e Zaranny should be used for the shortest time possible. The maximum duration of treatment is 14 consecutive days. Advise the patient to consult their doctor if they do not experience improvement following the recommended treatment period (see section 4.4). \u003cu\u003eElderly\u003c\/u\u003e This medicine should be used with caution in elderly patients as they are more predisposed to side effects (see section 4.4). \u003cu\u003ePediatric population (Children and adolescents under 16 years old)\u003c\/u\u003e The use of this medicated plaster is not recommended since there are insufficient data available on the safety and efficacy of the medicine in children and adolescents under 16 years of age (see section 4.3). In adolescents aged 16 years and older, if the product is needed for a treatment period longer than 7 days for pain relief or if symptoms worsen, the patient\/parents of the adolescent are advised to consult a doctor, as re-evaluation is necessary. \u003cu\u003ePatients with hepatic or renal insufficiency\u003c\/u\u003e For the use of Zaranny in patients with hepatic or renal insufficiency see section 4.4. \u003cu\u003eMethod of administration\u003c\/u\u003e Cut the bag containing the medicated plaster as indicated. Remove a medicated plaster, remove the plastic film used to protect the adhesive surface and apply the plaster to the joint or painful surface. If necessary, the plaster can be held in place using an elastic mesh bandage. Carefully close the envelope with the sliding closure. The patch must be used whole.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine does not require any particular storage temperature.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- The medicated plaster must only be applied to intact and healthy skin and must not be applied to damaged skin or open wounds and must not be applied when bathing or showering. - The medicated plaster must not come into contact with or be applied to the mucous membranes or eyes. - Do not use with an occlusive dressing that does not let air pass. - Treatment must be stopped immediately if a rash develops after applying the medicated plaster. - Do not administer simultaneously, topically or systemically, another medicinal product based on diclofenac or other NSAIDs. - The possibility of systemic adverse events produced by the application of topical diclofenac cannot be excluded if the preparation is used on a large skin surface and for a prolonged period (see product information relating to other systemic forms of diclofenac). Although systemic effects may be minimal, the patch should be used with caution in patients with impaired renal, cardiac or hepatic function, a history of peptic ulcer, intestinal inflammation or haemorrhagic diathesis. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients, as they are more susceptible to the onset of side effects. - Patients should be advised not to expose themselves to direct sunlight or sun lamps for approximately one day after removing the medicated plaster in order to reduce the risk of photosensitivity. - The medicated plaster should be used with caution in patients with asthma, chronic bronchial obstructive disease, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) who may react with asthma attacks, local inflammation of the skin or mucous membranes (Quincke's edema), urticaria or acute rhinitis after treatment with acetylsalicylic acid or other non-steroidal anti-inflammatory agents more often than other patients (see section 4.3). - In order to minimize the occurrence of side effects, it is recommended to use the lowest effective dose for the shortest duration necessary to control symptoms, without exceeding the approved maximum of 14 days (see sections 4.2 and 4.8). - The use, especially if prolonged, of this as well as other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. - Although systemic absorption is minimal, however the use of the medicated plaster, as of any drug that inhibits prostaglandin synthesis and cyclooxygenase, is not recommended in women intending to become pregnant (see section 4.6). - The administration of the diclofenac-based medicated plaster must be suspended in women who have fertility problems or who are undergoing fertility investigations (see section 4.6). This medicine contains \u003cb\u003emethyl parahydroxybenzoate\u003c\/b\u003e e \u003cb\u003epropyl parahydroxybenzoate\u003c\/b\u003e. They can cause allergic reactions (even delayed); This medicine contains 420 mg of \u003cb\u003epropylene glycol\u003c\/b\u003e per patch.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible. Clinical investigations carried out with the diclofenac-based medicated plaster, used in conjunction with other steroidal and non-steroidal anti-inflammatory drugs (salazopyrin, hydroxyquinoline, etc.), have not highlighted any interaction phenomena. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs (see section 4.8) is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions are listed by frequency, the most frequent first, using the following convention: very common (\u003e1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Pustular rash.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioedema, anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eUncommon: Petechiae.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eNot known: Burning sensation at the application site.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003eUncommon: Feeling hot.\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac is very low compared to the plasma levels measured after oral intake of diclofenac and the probability of systemic side effects (such as gastric, hepatic and renal disorders) is very low compared to the frequency of side effects associated with oral use of diclofenac. However, if Zaranny is used on large skin surfaces and for long periods of time, the appearance of systemic side effects is possible, especially at the gastrointestinal level due to the amount of active ingredient that is absorbed. The use of the product in combination with other drugs containing diclofenac must be avoided as it can give rise to phenomena of hypersensitivity to light, skin rash with vesicle formation, eczema, erythema and, in rare cases, severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome) (see paragraphs 4.4 and 4.5). \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported with diclofenac medicated plasters. Should systemic side effects occur due to incorrect use or accidental overdose (e.g. in children) with the product, the general supportive measures to be taken in case of intoxication with non-steroidal anti-inflammatory drugs are recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e The systemic concentration of diclofenac, compared to oral formulations, is lower after topical administration. Referring to the experience of treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may have negative effects on pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk has been thought to increase with dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligohydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of diclofenac medicated plaster, no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, Zaranny should not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4). \u003cu\u003eFertility\u003c\/u\u003e The administration of the medicated plaster must be suspended in women who have fertility problems or who are undergoing fertility investigations.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe application of diclofenac medicated plasters does not alter the ability to drive vehicles and use machinery.\u003c\/p\u003e","brand":"Doc Generici","offers":[{"title":"Default Title","offer_id":53495796924743,"sku":"045951023","price":22.23,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/doc-generici-srl-muscoridol-10-cerotti-medicati-dolore-muscolare-180-mg-farmacia-dottor-tili-1226919702.jpg?v=1773236830"},{"product_id":"14-mg-cerotto-medicato-10-cerotti-in-bustina-carta-pe-al-eaa","title":"Flector Unidie 14 mg 10 piroxicam medicated plasters","description":"\u003cp\u003eFlector Unidie is \u003cstrong\u003epiroxicam 14 mg\u003c\/strong\u003e in a medicated plaster. Piroxicam is a \u003cstrong\u003enon-steroidal anti-inflammatory\u003c\/strong\u003e, and the patch form serves to take it where it is needed without letting it all pass through the stomach: the levels in the blood that are reached this way are much lower than those of the tablet.\u003c\/p\u003e\u003cp\u003eThe name says the most useful thing to know. \u003cstrong\u003eUnidie\u003c\/strong\u003e it means \u003cstrong\u003eone patch every twenty-four hours\u003c\/strong\u003e, only one at a time, and never two on the same day. The cycle must not exceed \u003cstrong\u003eeight days\u003c\/strong\u003e. It applies only to the \u003cstrong\u003eintact skin\u003c\/strong\u003e, after having washed and dried the area well: rub a corner of the patch between your fingers to detach the protective film and place the adhesive part on the skin.\u003c\/p\u003e\u003cp\u003eOn the elbow and knee, which bend a lot, the RCP suggests a \u003cstrong\u003eretention bandage\u003c\/strong\u003e to be placed with the joint flexed, so the patch remains in place even when the joint opens.\u003c\/p\u003e\u003cp\u003eThe things that remain are that, being an NSAID, piroxicam also comes with it through the skin. The blood level is low but \u003cstrong\u003eIt varies a lot from person to person\u003c\/strong\u003e, therefore general effects cannot be excluded, especially on the stomach. And repeated use of skin products can cause \u003cstrong\u003eawareness\u003c\/strong\u003e: if redness, itching or burning appear at the application site, stop. Even better \u003cstrong\u003eavoid direct sun\u003c\/strong\u003e on the treated area, to avoid the risk of photosensitisation. This is the pack from \u003cstrong\u003e10 plasters\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Flector Unidie 14 mg 10 piroxicam medicated plasters used? What is it for?\u003c\/h3\u003e\u003cp\u003eFlector Unidie is indicated for the treatment of painful and inflammatory states of a rheumatic and traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Flector Unidie 14 mg 10 piroxicam medicated plasters?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eComposition\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eA medicated plaster contains: • active ingredient: piroxicam 14 mg. \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eExcipients\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eAcrylic copolymer, Eudragit E 100; non-woven fabric, silicone polyester.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow is Flector Unidie 14 mg 10 piroxicam medicated plasters taken?\u003c\/h3\u003e\u003cp\u003eDosage It is recommended to use only one medicated plaster at a time and replace it every 24 hours for a period of no more than 8 days. Do not apply two patches on the same day. Flector Unidie is to be used exclusively on intact skin. Method of administration For cutaneous use only. After having carefully washed and dried the painful area, rub one of the corners of Flector Unidie between your fingers to remove the protective film and apply the adhesive part directly to the skin. In the event that Flector Unidie must be applied to joints with greater mobility, such as the elbow or knee, it is advisable to use a retention bandage to be applied to the flexed joint, in order to keep the patch in place. Do not exceed the recommended doses. Avoid contact with eyes and mucous membranes.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Flector Unidie 14 mg 10 piroxicam medicated plasters not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eContraindications\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eFlector Unidie is contraindicated in the following cases: • hypersensitivity to the active ingredient (piroxicam) or to any of the excipients (see the section \"What is the composition of Flector Unidie 14 mg 10 piroxicam medicated plasters?\"); • patients in whom substances with a similar mechanism of action (NSAIDs) have caused hypersensitivity reactions ((see the section \"What are the warnings of Flector Unidie 14 mg 10 piroxicam medicated plasters?\")); • patients with active peptic ulcer; • patients with bronchial asthma; • patients with a history of gastrointestinal bleeding due to NSAIDs; • patients on anticoagulant therapy; • pregnancy and breastfeeding ((see the section \"Can Flector Unidie 14 mg 10 piroxicam medicated plasters be used during pregnancy and breastfeeding?\")); • children under 12 years of age. Flector Unidie patch should not be used on open wounds or lesions, but only on intact skin.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSide effects\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThe use of the medicine can cause local irritative or allergic skin reactions such as erythema, itching, burning, contact dermatitis, numbness and tingling at the application site; cases of extensive and serious dermatological lesions such as urticaria, Quincke's edema, erythema multiforme have been reported with this type of medicine. Larger and more severe photosensitivity reactions and skin and mucosal reactions, including asthma attacks, are possible. Systemic adverse reactions following the topical use of piroxicam are unlikely; since the plasma levels obtained are lower than those measured after systemic administration but highly variable from individual to individual, it is not possible to exclude, especially in the case of prolonged therapies beyond the recommended term and non-observance of contraindications and warnings, the appearance of systemic side effects, especially at a gastrointestinal level ((see the section \"What are the warnings for Flector Unidie 14 mg 10 piroxicam medicated plasters?\")). The possible appearance of general side effects or at the point of application requires suspension of therapy. Cases of fixed drug eruption with unknown frequency (frequency cannot be estimated from the available data) have been reported with piroxicam ((see section \"What are the warnings for Flector Unidie 14 mg 10 piroxicam medicated plasters?\")). Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can change the effect of Flector Unidie 14 mg 10 piroxicam medicated plasters?\u003c\/h3\u003e\u003cp\u003eThe use of piroxicam-based patches is unlikely to have interactions with other medicines. However, the possibility of competition between the absorbed piroxicam and other drugs with high binding to plasma proteins cannot be excluded. Do not use the medicine together with other drugs for oral or local use, containing piroxicam or other NSAIDs.\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Flector Unidie 14 mg 10 piroxicam medicated plasters be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003ePregnancy and breastfeeding Flector Unidie is contraindicated during pregnancy and breastfeeding and is not recommended in women intending to become pregnant. Fertility Administration should be suspended in women with fertility problems or who are undergoing fertility investigations.\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Flector Unidie 14 mg 10 piroxicam medicated plasters?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings and precautions\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThe serum levels achieved with Flector Unidie were significantly lower than those obtained through oral administration but with strong individual variability, therefore the onset of systemic side effects, especially at the gastrointestinal level, cannot be ruled out. Analgesics, antipyretics, non-steroidal anti-inflammatory drugs, including piroxicam, can cause hypersensitivity reactions, potentially serious even in subjects not previously exposed to this type of drugs. These include asthma attacks, skin rashes, allergic rhinitis and anaphylactic-type reactions. Flector Unidie should be used with caution in subjects with chronic obstructive bronchial diseases, allergic rhinitis or inflammation of the nasal mucosa (nasal polyps) in which asthmatic attacks or localized inflammatory reactions of the skin and mucosa (Quincke's edema) are more frequent. Use caution in patients with a history of peptic ulcer, in patients with a history of gastrointestinal bleeding not secondary to the administration of NSAIDs or with other bleeding disorders, in patients with Crohn's disease or ulcerative colitis, with severe hepatic or renal dysfunction or with heart failure. Prolonged or repeated use of products for skin use can give rise to sensitization phenomena. In the presence of hypersensitivity reactions it is necessary to interrupt therapy. Caution should be used when treating elderly patients who are generally more susceptible to adverse events. After a short therapy without results, consult your doctor. To avoid any phenomena of hypersensitivity or photosensitization, avoid exposure to direct sunlight. Skin reactions Cases of fixed drug eruption (FDE) have been reported with piroxicam. Piroxicam should not be reintroduced in patients with a history of piroxicam-related FDE. A potential cross-reaction with other oxicams may occur. Pediatric population Keep the medicine out of the sight and reach of children.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eOverdose\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThere are no known cases of overdose. In case of overdose with evident clinical manifestations, immediately institute symptomatic therapy and apply the common emergency measures of the case.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDriving vehicles and using machinery\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eFlector Unidie does not interfere with the ability to drive vehicles and use machines.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Flector Unidie 14 mg 10 piroxicam medicated plasters stored?\u003c\/h3\u003e\u003cp\u003eNo particular storage conditions are necessary.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Flector Unidie 14 mg 10 piroxicam medicated plasters?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e10 medicated plasters of 14 mg\u003c\/strong\u003e, in paper, polyethylene, aluminum and EAA sachets.\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Ibsa","offers":[{"title":"Default Title","offer_id":54954303652167,"sku":"038354039","price":25.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ibsa-farmaceutici-italia-srl-14-mg-cerotto-medicato-10-cerotti-in-bustina-carta-pe-al-eaa-farmacia-dottor-tili-1257817163.jpg?v=1789016140"}],"url":"https:\/\/www.dottortili.com\/en\/collections\/farmaci-e-cerotti-antidolorifici-topici.oembed?page=2","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}